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Abstract 
KEN NOGUCHI. Interleukin-like EMT Inducer (ILEI, FAM3C) in Melanoma Partial 
Phenotype Switching. (Under the direction of PHILIP H. HOWE).  
 
Interleukin like EMT-Inducer (ILEI, FAM3C) is a secreted factor that 
contributes to the epithelial-to-mesenchymal transition (EMT), a cell biological 
process that confers metastatic properties to a tumor cell. Initially, we found that 
ILEI mRNA is highly expressed in melanoma metastases but not in primary 
tumors, suggesting that ILEI contributes to the malignant properties of melanoma. 
While melanoma is not an epithelial cell-derived tumor and does not undergo a 
traditional EMT, melanoma undergoes a similar process known as phenotype 
switching in which high MITF (micropthalmia-related transcription factor) 
expressing proliferative cells (MITF-high) switch to a low expressing invasive 
state (MITF-low). We observed that MITF-high proliferative cells express low 
levels of ILEI (ILEI-low) and MITF-low invasive cells express high levels of ILEI 
(ILEI-high). Next, we used in vitro and in vivo assays to show that knockdown of 
ILEI attenuates invasive potential but does not affect MITF expression or 
chemoresistance. We used gene expression analysis to show that ILEI regulates 
several genes involved in the MITF-low invasive phenotype including JARID1B 
(KDM5B), HIF-2a (EPAS1), and BDNF. Gene set enrichment analysis suggested 
that ILEI-regulated genes are enriched for JUN signaling, a known regulator of 
the MITF-low invasive phenotype. Additionally, we found that inducing phenotype 
switching towards the MITF-low invasive state increases ILEI mRNA expression, 
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whereas phenotype switching towards the MITF-high proliferative state 
decreases ILEI mRNA expression. Mechanistically, we found that the 
transcription factor upstream stimulatory factor 1 (USF1) regulates FAM3C 
transcription. In conclusion, we demonstrate that phenotype switching regulates 
ILEI expression through USF1, and that ILEI in turn regulates the invasive 




 Melanoma is a malignant proliferation of melanocytes, the pigment-
producing cell in the skin. While melanoma makes up <1% of skin cancers by 
prevalence, it accounts for the vast majority of skin cancer deaths (Siegel et al., 
2017) because it commonly metastasizes early in the disease course and 
melanoma cells can survive in dormant conditions for years. A famous example 
of this metastatic tendency is highlighted in a case report describing an unusual 
cancer presentation in a patient who had undergone a kidney transplant in 1998 
(MacKie et al., 2003). The patient presented one year later in 1999 with a breast 
nodule initially thought to be primary breast cancer. However, upon biopsy it was 
found to be a secondary melanoma that had metastasized from an unknown site. 
Soon after she developed abdominal pain, which was caused by secondary 
melanoma nodules growing on her transplanted kidney. She died of metastatic 
melanoma in 2000. A look back at the records revealed that the kidney donor 
had a primary melanoma surgically removed in 1982, but she had been cancer 
free for over 15 years until she died of non-cancer related causes. To summarize, 
the original kidney donor had a small primary melanoma surgically removed with 
no complications for fifteen years until her death when her kidney was 
transplanted into a patient who rapidly succumbed to metastatic melanoma. 
During those fifteen years, melanoma cells were dormant in her kidney waiting 
for the perfect time to strike. Unfortunately for the kidney transplant recipient this 
time came when she was on the usual course of post-transplant 
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immunosuppresants, allowing the melanoma to proliferate. Clearly, we need to 
understand more molecular details of melanoma metastatic progression in order 
to help melanoma patients. Additionally, melanoma should be a useful model to 
understand molecular details of metastatic progression that could be applicable 
to other cancers.  
In order to understand melanoma it is first important to look at the origins 
of melanoma, which begin at the melanocyte. During embryonic development 
multipotent neural crest cells delaminate from the neural tube by undergoing an 
epithelial-to-mesenchymal transition (EMT) to lose cell-cell junction proteins such 
as E-cadherin and migrate to peripheral sites (Greenburg and Hay, 1982; 
Simoes-Costa and Bronner, 2015; Theveneau and Mayor, 2012; Trelstad et al., 
1967; Trelstad et al., 1966). EMT was originally observed by developmental 
biologists working on chick embryogenesis (Trelstad et al., 1967; Trelstad et al., 
1966) and later described as a phenomenon that could be induced in vitro as 
Greenburg and Hay showed that adult well-differentiated epithelial cells can be 
induced to a mesenchymal phenotype by interaction with extracellular matrix 
(Greenburg and Hay, 1982). Following EMT-mediated migration to the skin, 
melanocytes reside in the basal epidermal layer of human skin where they serve 
their unique function to produce melanin and confer skin pigmentation. It was first 
observed that melanocytes interact with keratinocytes in an “epidermal melanin 
unit” in which one melanocyte interacts with and provides melanin to 36 
surrounding keratinocytes (Fitzpatrick and Breathnach, 1963). Melanocytes thus 
express cell adhesion molecules such as E- and P-cadherin in order to maintain 
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interactions with keratinocytes (Tang et al., 1994). These melanocyte-
keratinocyte interactions are critical for melanin transfer from melanocyte to the 
rest of the skin.  
The causes of melanoma are multifaceted. The most commonly 
identified cause is ultraviolet (UV) light-induced skin damage, which highlights 
the necessity of preventative measures such as sunscreen (Jhappan et al., 
2003). At the molecular level, UV radiation induces DNA damage indicated by 
thymine dimers, and these DNA damage-induced mutations can initiate 
melanomas. Additionally, UV radiation induces an immunosuppressive 
microenvironment to promote melanomagenesis. Mechanistically, UV 
radiation promotes melanocyte-specific expression of CCL8 ligand to recruit 
CCR2+ macrophages, which then secrete interferon-g (IFN-g) to suppress the 
local immune response and promote melanoma survival (Zaidi et al., 2011).   
Genetic lesions can also cause melanoma, which highlights the value of 
understanding melanoma on a molecular level. There are many known 
genetic alterations in melanoma including chromosomal changes and 
oncogenic mutations. The most common alteration is the oncogenic BRAF 
V600E mutation found in 66% of melanomas. This mutation confers alters 
mitogen-activated protein kinase (MAPK) signaling by destabilizing the 
inactive conformation of B-Raf, thus rendering B-Raf constitutively ative 
(Davies et al., 2002). However, this mutation is also found in benign moles 
and is known to induce growth arrest in mouse models (Michaloglou et al., 
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2005; Vredeveld et al., 2012). The progression to a full-blown melanoma 
requires additional mutations including TP53 or PTEN (Dankort et al., 2009; 
Patton et al., 2005). In addition to BRAF V600E, there are two common 
genetic changes in melanoma including chromosome loss of 9p, which 
contains CDKN2A, and 10q, which contains PTEN (Chin et al., 2006). 
CDKN2A codes for two critical inhibitors of the cell cycle, INK4A and ARF, 
thus in the absence of CDKN2A the cell cycle is accelerated. INK4A codes for 
p16, the cyclin-dependent kinase 4/6 inhibitor, which causes G1 cycle arrest. 
ARF codes for p14, which inhibits the E3 ligase of p53, MDM2. p53 is known 
as a major player in the DNA damage response because of its role in 
triggering apoptosis and cell cycle arrest. Finally, PTEN codes for 
phosphatase and tensin homolog, which is the primary inhibitor of the AKT 
signaling pathway.  
For years the standard of care for melanoma has been the alkylating 
agent dacarbazine, but studies have shown that dacarbazine shows a 
response in only 23% of malignant melanoma patients (Lui et al., 2007). 
Additionally, dacarbazine has side effects including but not limited to: sterility, 
severe infections, and liver damage. Therefore, there has been a major push 
over the past fifteen years to develop targeted therapies for melanoma. The 
breakthrough came in 2008 when Plexxikon and Genentech used a technique 
called scaffold-based drug discovery to create the targeted kinase inhibitor 
known as vemurafenib or Zelboraf (Bollag et al., 2010; Chapman et al., 2011; 
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Flaherty et al., 2010; Tsai et al., 2008; Wagle et al., 2011). Vemurafenib 
targets only the oncogenic version of BRAF by interacting with the ATP-
binding site, and it was shown to be highly effective against melanomas that 
possess the BRAF V600E mutation. Unfortunately, vemurafenib succumbs to 
rapid relapse due to a variety of mechanisms including MAPK reactivation by 
secondary MEK mutations and AKT activation by PDGFRb upregulation (Shi 
et al., 2014; Trunzer et al., 2013).  
In addition to the kinase inhibitor vemurafenib, a second breakthrough 
treatment for melanoma was the immune checkpoint inhibitor targeting 
programmed cell death protein 1 (PD-1), nivolumab (Drake et al., 2014). PD-1 is 
an immunoinhibitory receptor that is expressed on activated T, B, and myeloid 
cells (Keir et al., 2008). Mechanistically, PD-1 binds its ligand PD-L1 to inhibit T-
cell receptor-mediated proliferation and the secretion of pro-inflammatory 
cytokines such as IFN-g and IL-10 (Freeman et al., 2000). Therefore, nivolumab 
functions as a blocking antibody to inhibit the PD-1-mediated suppression of the 
immune system, thus enhancing immune-mediated tumor killing. Some patients 
treated with nivolumab exhibit durable disease control but other patients fail to 
respond at all (Hodi et al., 2010). Combined treatment of both kinase inhibitors 
and immunotherapies has also been suggested (Hu-Lieskovan et al., 2014). 
There is clear in vitro evidence for such a combination as Boni et al, have shown 
that vemurafenib increases the efficacy of immunotherapies by promoting the 
expression of melanocyte-specific antigens such as gp100 and MART-1 (Boni et 
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al., 2010). In addition, Steinberg et al have shown that vemurafenib alleviates the 
ability of melanoma to recruit immunosuppressive regulatory T cells and myeloid-
derived suppressor cells (Steinberg et al., 2014). Unfortunately, the combination 
treatments have proved too toxic to use in the clinic (Ribas et al., 2013). In order 
to build upon these breakthrough therapies, it is critical to develop a molecular 
understanding of why therapies such as vemuarfenib and nivolumab fail. One 
proposed hypothesis is that melanoma cells undergo phenotype switching to gain 
properties of therapy resistant cells (Falletta et al., 2017; Hugo et al., 2016; 
Richard et al., 2016). 
Phenotype switching is a phenomenon that was originally described based 
on gene expression data, which revealed that the transcriptomes of melanoma 
cell lines (Hoek et al., 2006; Widmer et al., 2012) and patient samples (Verfaillie 
et al., 2015) could be separated into distinct proliferative and invasive states. 
These two states are most often distinguished by the master melanocyte lineage 
regulator MITF (micropthalmia-related transcription factor). The proliferative state 
is marked by high MITF expression (MITF-high) and the invasive state is marked 
by low MITF expression (MITF-low; a model is depicted below in Fig 1).  
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Fig 1. Model of phenotype switching in melanoma. Epi: Epithelial-like. Mes: 
Mesenchymal-like. MITF: Micropthalmia-associated transcription factor.  
 
Mutations in MITF lead to mice with a wide variety of problems including 
lack of pigmentation and small eyes (Hodgkinson et al., 1993). Functionally, 
MITF is a member of the basic helix-loop-helix-leucine zipper family, which binds 
to an E-box motif (CATGTG) and activates the transcription of melanocyte 
differentiation genes such as pigment producing genes PMEL, which encodes 
the premelanosome protein, and TYR, which encodes tyrosinase (Carreira et al., 
2006; Loercher et al., 2005; McGill et al., 2002; Shibahara et al., 2000; Yasumoto 
et al., 1997). In addition to pigmentation genes MITF also regulates cell cycle 
progression genes such as the TBX2 transcription factor, which promotes 
senescence bypass by inducing histone deacetylation at the p21 promoter, and 
the kinase CDK2 (Carreira et al., 2000; Du et al., 2004; Prince et al., 2004; 
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Vance et al., 2005). Accordingly, the MITF-high proliferative state is 
characterized by a high proliferative capacity and differentiation state, but low 
motility (Hoek et al., 2008; Hoek et al., 2006).  
On the other hand, the invasive state is a MITF-low dedifferentiated state 
that resembles the mesenchymal state in EMT. At the molecular level MITF-low 
cells express EMT-related molecules including the cell-adhesion regulator N-
Cadherin (CDH2), the transcription factor ZEB1 (ZEB1), and TGF-b family 
ligands such as inhibin bA (INHBA) (Hoek et al., 2006). Functionally, MITF-low 
cells have increased motility and are resistant to chemotherapies. While the 
proliferative state is marked by the expression of MITF, the invasive state is 
simply marked by a lack of MITF because a dominant regulator of the invasive 
state is yet to be described. There are many proposed regulators of the invasive 
state including the neural crest stem cell marker p75 low affinity nerve growth 
factor receptor NGFR, non-canonical WNT ligand WNT5A, as well as the 
receptor tyrosine kinase AXL (Dissanayake et al., 2008; Dissanayake et al., 
2007; Konieczkowski et al., 2014; Morrison et al., 1999; Muller et al., 2014; 
Weeraratna et al., 2002). Several canonical regulators of EMT including ZEB1 
have also been described as drivers of the phenotype switch (Richard et al., 
2016). However, one interesting point to note regarding EMT factors in 
phenotype switching is that EMT factors do not perfectly correlate with phenotype 
switching factors. For instance, during phenotype switching ZEB1 and ZEB2 are 
oppositely regulated and invasive cells have high ZEB1 and low ZEB2, whereas 
proliferative cells have low ZEB1 and high ZEB2 (Caramel et al., 2013; Denecker 
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et al., 2014). In melanoma cell lines ZEB1 is a direct repressional target of MITF, 
so ZEB1 is not expressed in the MITF-high proliferative state whereas MITF-low 
invasive cells allow for ZEB1 expression (Denecker et al., 2014). The mechanism 
of regulation for ZEB2 is still unknown, and importantly the different downstream 
targets of ZEB1 and ZEB2 in melanoma have yet to be described. In addition to 
EMT regulators like ZEB1, large transcriptomic studies have identified JUN and 
TEAD4 as major regulators of the invasive phenotype (Verfaillie et al., 2015). 
JUN encodes an oncogenic transcription factor c-Jun that couples with c-Fos to 
make up the AP-1 transcription factor. Several groups have confirmed the 
contribution of JUN to the invasive state (Ramsdale et al., 2015; Riesenberg et 
al., 2015). TEAD4 is a transcription factor that promotes tumorigenesis through 
the Hippo signaling cofactor YAP.  
While EMT was originally discovered by developmental biologists, EMT is 
now recognized as a process that is critical to cancer progression. Transitioned 
mesenchymal cells have several properties that allow them to contribute to 
cancer progression including the capacity to degrade basement membrane, 
survive in suspension, resist chemotherapy and oxidative stress, and self-renew 
as cancer stem cells (Nieto et al., 2016). EMT is regulated by several 
mechanisms, the foremost being TGF-b (Massague, 2008; Oft et al., 1998). TGF-
b regulates EMT at the transcriptional level by activating EMT-transcription 
factors such as ZEB and Snail, which bind to E-box (CANNTG) promoter 
elements to repress the transcription of epithelial genes such as CDH1 (E-
Cadherin) (Batlle et al., 2000; Cano et al., 2000; Comijn et al., 2001; Hajra et al., 
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2002). TGF-b regulates EMT at the post-transcriptional level by inhibiting the 
expression of miR-200 family, which maintains the epithelial phenotype by 
repressing ZEB (Bracken et al., 2008; Gregory et al., 2008; Park et al., 2008). 
Our research group and others have also described translational regulation of 
EMT (Brown et al., 2016; Chaudhury et al., 2010; Evdokimova et al., 2009; 
Howley et al., 2015; Hussey et al., 2011; Hussey et al., 2012). Briefly, the 
mechanism we described revolves around the RNA binding protein hnRNP-E1 
(PCBP1). hnRNP-E1 binds to a structural motif known as the BAT (b activated 
translation) element in the 3’ UTR of EMT-related mRNA molecules and inhibits 
their translation. Upon TGF-b stimulation, AKT2 phosphorylates hnRNP-E1 to 
dissolve the translational repressor complex, thus allowing for active translation 
of EMT-specific mRNA molecules. In this dissertation we focus on one such 
target, Interleukin-like EMT Inducer (ILEI, FAM3C [family with sequence similarity 
3 C]).  
FAM3C or ILEI was originally identified using a secondary structure-based 
prediction strategy to discover novel cytokines (Zhu et al., 2002). It was predicted 
that the FAM3 family of proteins would have secreted cytokine activity due to the 
presence of a four-helix-bundle commonly observed in the interleukin family of 
cytokines. Subsequently, ILEI has been described as an inducer of the epithelial-
to-mesenchymal transition (Csiszar et al., 2014; Katahira et al., 2010; Lahsnig et 
al., 2009; Song et al., 2014; Waerner et al., 2006). However, the data across 
these manuscripts are inconsistent with each other. For instance, the first major 
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manuscript on ILEI and cancer suggested that ILEI was sufficient to induce EMT 
in non-tumorigenic Ras wild-type EpH4 cells. They demonstrated this by 
overexpressing ILEI in EpH4 cells to induce the following phentoypes: increased 
tumorigenesis, increased wound healing, and inhibition of E-cadherin and 
induction of vimentin expression (Waerner et al., 2006). A follow-up paper 
showed that immortalized hepatocytes require oncogenic Ras to promote EMT 
(Lahsnig et al., 2009). Finally, in their most recent paper on ILEI they use the 
EpC40 Ras mutant cell line, and find that overexpression of ILEI alone did not 
induce EMT (Csiszar et al., 2014). Taken in sum, it is still unclear if ILEI requires 
additional cofactors to induce its EMT function, or if it is sufficient to induce EMT 
alone in some circumstances.  
In addition to the cancer EMT model, ILEI contributes to Alzheimer’s 
progression, bone development, and hepatic glucose regulation (Bendre et al., 
2016; Chen et al., 2017; Hasegawa et al., 2014; Liu et al., 2016; Maatta et al., 
2016). Alzheimer’s is a neurodegenerative disease that is in part caused by an 
accumulation of the amyloid-b peptide (Ab). Ab is produced from amyloid protein 
precursor following cleavage by b- and g-secretase (De Strooper et al., 2012). In 
order to therapeutically target Ab production, g-secretase inhibitors have been 
developed. However, g-secretase is also involved in the activation of Notch 
signaling and a major challenge has been inhibiting g-secretase-mediated Ab 
production without interfering with g-secretase-mediated Notch signaling (De 
Strooper et al., 1999). In 2014 Hasegawa et al attempted to address this problem 
	 12	
by conducting mass spectrometry on proteins that could be affinity purified with 
the g-secretase subunit PEN-2 (presenilin enhancer-2) (Hasegawa et al., 2014). 
Interestingly, they pulled out ILEI as a PEN-2 interaction partner. They go on to 
show that ILEI inhibits Ab production through its interaction with the g-secretase 
complex without affecting Notch signaling. A follow-up study conducted an 
expression characterization of ILEI in the brain, which revealed that ILEI is 
expressed in neurons and ependymal cells but not glia or endothelial cells (Liu et 
al., 2016). In addition, brain ILEI expression declines with age and Alzheimer’s 
patients have less ILEI than healthy age-matched patients. These findings are 
consistent with their previous findings that ILEI inhibits Ab production, which is a 
surrogate marker for Alzheimer’s disease.  
Recently Määtä et al reported a whole body FAM3C (ILEI) knockout 
mouse and the major phenotype they observed was weakened bone formation 
(Maatta et al., 2016). Their follow-up paper showed that ILEI regulates bone 
development through regulation of RUNX2, which is involved in osteoblast 
differentiation (Bendre et al., 2016). One point to highlight here is that both 
osteoblasts, neurons, and melanocytes derive from neural crest cells (Maguire et 
al., 2015; Simoes-Costa and Bronner, 2015).  
Chen et al observed a metabolic function for ILEI, first observing a 
downregulation of ILEI in the liver of obese diabetic mice (Chen et al., 2017). 
Additionally they found that liver-specific reconstitution of ILEI in the obese 
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diabetic mice ameliorated their excessive fasting blood glucose and fatty liver 
disease. Mechanistically they found that this was due to an activation of AKT. 
The only described regulators of ILEI are post-translational proteolysis 
(Csiszar et al., 2014), autophagy (Kraya et al., 2015), the ubiquitin/proteasome 
system (Sun et al., 2016), and TGF-b/AKT2/hnRNP-E1 (Chaudhury et al., 2010; 
Hussey et al., 2011; Waerner et al., 2006). One goal of this dissertation is to 
describe a novel mode of ILEI regulation at the transcriptional level. While there 
are no reported transcriptional regulators of ILEI, Pilipenko et al conducted an 
analysis of the FAM3C promoter and postulated that the NKX5.1 transcription 
factor could be a transcriptional regulator of ILEI (Pilipenko et al., 2004).  
A major hindrance to the study of ILEI as a secreted molecule has been 
the challenge of producing a biologically active recombinant ILEI, due in part to 
the post-translational processing of ILEI and also the lack of a consistent 
biological readout for ILEI activity (Csiszar et al., 2014; Lahsnig et al., 2009; 
Waerner et al., 2006). Therefore, a critical need to promote our molecular 
understanding of ILEI is the identification of transcriptional targets to use as 
markers of ILEI activity. While ILEI has only been described in two papers in the 
melanoma field, the data presented herein suggest that ILEI contributes to 
melanoma biology (Girotti et al., 2011; Kraya et al., 2015). Thus, gene 
expression analysis was conducted on melanoma cell lines to identify possible 
ILEI target genes. 
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 This dissertation will characterize the biological function and 




Materials & Methods 
 
Animal studies 
All procedures were approved by the Institutional Animal Care and Use 
Committee at the Medical University of South Carolina. Xenograft experiments 
were conducted as follows: flank injections into 6-8 week old NOD/SCID mice 
were performed with 1205Lu cells expressing shSCR or shILEI 3 (1 x 106 cells in 
100 µL of phosphate-buffered saline). After 8 weeks, mice were sacrificed, and 
lungs and primary tumors were harvested. Lung colonization experiments were 
conducted as follows: tail vein injection into 6-8 week old mice were performed 
with 1205Lu cells expressing shSCR or shILEI 3 (1 x 105 cells in 100 µL of 
phosphate-buffered saline). After 8 weeks, mice were sacrificed, and lungs were 
harvested. Organs were formalin-fixed and paraffin-embedded. Histopathological 
analysis was conducted by Hollings Cancer Center Biorepository & Tissue 
Analysis Shared Resource.  
 
Biotin DNA pulldown 
 DNA pulldown assays were conducted with 5’-biotinylated double-
stranded annealed oligonucleotides corresponding to FAM3C promoter from -200 
to -110 upstream of the TSS. A mutant E-box construct was used in which the E-
box at -162 to -156 was mutated from CACGTG to CAAATG. A 5’-biotinylated 
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double-stranded annealed oligonucleotide of a random sequence was used as a 
negative control (SCR).  
Nuclear extracts were isolated by harvesting cells in lysis buffer (10 mM 
HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.05 % NP40, pH 7.9, 
protease and phosphatase inhibitor tab) and pelleting cell nuclei. Pellets were 
incubated for 30 min on ice in nuclei extraction buffer (5 mM HEPES, 1.5 mM 
MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 26% glycerol, pH 7.9, protease and 
phosphatase inhibitor tab) and NaCl added to a final concentration of 300 mM. 
Samples were homogenized by passing through a 28 g syringe 20 times. 
Samples were incubated on ice for 30 min and centrifuged. The supernatants 
were considered the nuclear extract. 20 μg nuclear extract was reserved as 5% 
input.  
Preclear beads were prepared as follows: 5’-biotinylated random 
oligonucleotide (SCR) was bound to streptavidin agarose beads (50 μl slurry + 
10 μg oligo; ThermoFisher; Waltham, MA; USA) for 1h on a rotator at room 
temperature. IP beads were prepared as follows: 5’-biotinylated FAM3C promoter 
WT or E-box mutant (CACGTG to CAAATG) was bound to streptavidin agarose 
beads (50 μl slurry + 1 μg oligo; ThermoFisher; Waltham, MA; USA) for 1h on a 
rotator at room temperature. Preclear was conducted as follows: 400 μg nuclear 
extract was incubated with preclear beads for 1h on a rotator at room 
temperature. The sample was centrifuged and thel supernatant was incubated 
with IP beads overnight on a rotator at 4°. The beads were washed in PBS/0.1% 
Triton X-100 and resolved by SDS-PAGE, transferred to nitrocellulose, and 
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probed using antibody against USF1 (C-20; sc-229; Santa Cruz; Dallas, TX; 
USA; 1:1,000).  
 
Cell culture conditions 
The following human melanoma cell lines were used: 501-Mel, Sk-Mel-28, 
WM3912, WM983B, WM793, 1205Lu, and WM9. These cell lines were 
purchased from ATCC, Coriell, or were a generous gift from Dr. J. Alan Diehl or 
Dr. Alain Mauviel. The following normal human melanocyte cell line was used: 
Primary Epidermal Melanocytes; Normal, Human, Neonatal. This cell line was 
purchased from ATCC (Manassas, VA; USA). All cell lines were cultured at 37°, 
5% CO2 in RPMI-1640 (Hyclone; Logan, UT; USA) supplemented with 10% FBS 
(Atlanta Biologicals; Flowery Branch, GA; USA), Antibiotic-Antimycotic (100x; 
ThermoFisher; Waltham, MA; USA), and prophylactic plasmocin (InvivoGen; San 
Diego, CA; USA).  
Stable cell lines were generated by lentiviral transduction with polybrene 
(8 µg/ml; Sigma-Aldrich; St. Louis, MO; USA). 24h post-transduction the media 
was changed, and 48h post-transduction the cells were selected and cultured 
with 0.125 - 0.5 µg/ml puromycin, 0.5 - 5 µg/ml blasticidin (InvivoGen; San Diego, 
CA; USA). Pools of stably transduced cells were analyzed.  
Transient transfections were conducted with X-tremeGENE 9 DNA 
transfection reagent (Sigma-Aldrich; St. Louis, MO; USA) using 0.5 µg DNA and 
1.5 µL X-tremeGENE 9 in 100 µL Opti-MEM I Reduced Serum Medium 
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(ThermoFisher; Waltham, MA; USA) per 6 well plate. 24h post-transfection the 
media was changed, and 48h post-transfection the cells were harvested. siRNA 
transfections were conducted with Lipofectamine 3000 (ThermoFisher; Waltham, 
MA; USA) with 25 pmol siRNA and 7.5 µL Lipofectamine RNAiMAX in 250 µL 
Opti-MEM I Reduced Serum Medium (ThermoFisher; Waltham, MA; USA) per 6 
well plate. 24h post-transfection the media was changed, and 72h post-
transfection the cells were harvested. siRNA molecules (Cell Signaling; Danvers, 
MA; USA) used in this study are listed below in Table 1.  
 
Table 1. sh and siRNA sequences. 
shRNA and siRNA Referred to herein as Sequence 
pLKO.1-puro Non-






















































Cell proliferation assays 
Cells (1 x 105, 1 ml of complete medium) were seeded in a 6 well plate, 




Vemurafenib, U0126, and LY-294002 were purchased from Selleckchem 
(Houston, TX; USA). EGF, chloroquine and MG-132 were purchased from 
Sigma-Aldrich (St. Louis, MO; USA). All compounds were stored in DMSO at -




 ChIP protocol was modified from Carey et al (Carey et al., 2009). Briefly, 
1.5 x 107 cells were fixed in 1% formaldehyde for 10 minutes at room 
termperature and quenched in 125 mM glycine. Cells were harvested in lysis 
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buffer (5 mM PIPES [pH 8], 85 mM KCl, 0.5% NP-40), and centrifuged for 10 min 
(3,000 rpm, 4°). Supernatant (cytosolic fraction) was removed, and pellet was 
resuspended in nuclei lysis buffer (50 mM Tris [pH 8], 10 mM EDTA, 1% SDS, 
protease and phosphatase inhibitor tab). Nuclear extracts were sonicated for 10 
min (30 sec on - 30 sec off), and cleared by centrifugation (2x, 10 min, 13,000 
rpm, 4°). The supernatant was considered the chromatin fraction. 100 μg of 
chromatin samples were precleared for 2h at 4° with 30 μl slurry ChIP-Grade 
Protein G Agarose Beads (9007; Cell Signaling; Danvers, MA; USA). Resulting 
supernatants were incubated overnight on a rotator at 4° with 5 μg of control 
Mouse (G3A1) mAb IgG1 Isotype Control (5415; Cell Signaling; Danvers, MA; 
USA) or USF1 antibody (C-20). 30 μl slurry ChIP-Grade Protein G Agarose 
Beads was added to each sample for 2h on a rotator at 4°. Beads were washed 
4x in high-salt wash buffer (50 mM HEPES [pH 7.9], 500 mM NaCl, 1 mM EDTA, 
0.1% SDS, 1% Triton X-100, 0.1% deoxycholate) each time incubating for 10 min 
on a rotator at room temperature. Beads were next washed 2x in TE buffer each 
time incubating for 10 min on a rotator at room temperature. Beads were 
resuspended in 300 μl elution buffer (50 mM Tris [pH 8], 10 mM EDTA, 1% SDS) 
+ 20 μg RNase A (R1253; Thermo Fisher Scientific; Waltham, MA; USA) and 
incubated on a 55° heat block for 2h. 1.6 mU of proteinase K (P8107S; New 
England BioLabs; Ipswitch, MA; USA) were added prior to another incubation on 
a 55° heat block for 2h. The samples were transferred to a 65° heat block for 
overnight elution. The samples were purified in 30 μl H20 using GeneJET PCR 
Purification Kit (K0702; Thermo Fisher Scientific; Waltham, MA; USA). PCR was 
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conducted using primers specific for human FAM3C promoter (300 bp to 80 bp 
upstream of TSS), human TYR promoter or human HMOX1 promoter (Galibert et 
al., 2001; Hock et al., 2004) 
 
Clonogenic assay 
Cells (1-5 x 104, 1 ml of complete medium) were seeded in a 10 cm plate. 
After 24h cells were treated with drug as indicated. After 7d cells were fixed in 
3.7% PFA (Sigma-Aldrich; St. Louis, MO; USA) and stained with 0.2% crystal 
violet/20% methanol.  
 
Constructs 
Lentiviral shRNAs were obtained from the MUSC Hollings Cancer 
Center shRNA Shared Resource Technology. All shRNA vectors used in this 
study are listed in Table 1. The following constructs were used in this study: 
pcDNA3-cmyc (a gift from Wafik El-Deiry [Addgene plasmid # 16011]) (Ricci 
et al., 2004), pCDNA3-HA-human MYCN (a gift from Martine Roussel 
[Addgene plasmid # 74163]) (Vo et al., 2016), pMXs-Hu-L-Myc (a gift from 
Shinya Yamanaka [Addgene plasmid # 26022]) (Nakagawa et al., 2010), 
pEGFP-N1-TFEB (a gift from Shawn Ferguson [Addgene plasmid # 38119])   
(Roczniak-Ferguson et al., 2012), pEGFP-N1-TFE3 (a gift from Shawn 
Ferguson [Addgene plasmid # 38120]) (Roczniak-Ferguson et al., 2012), 
pCMV-Tag4A-MITF-M (wt) (a gift from Yardena Samuels [Addgene plasmid # 
31151]), and USF1, CREB3L2, ILEI, and ID2 coding sequence constructs in 
	 22	
pLX304 were generated by David Root and supplied by DNASU (Cormier et 
al., 2010; Cormier et al., 2011; Seiler et al., 2014; Yang et al., 2011). The 
corresponding empty vector for human L-MYC was constructed by digesting 
pMXs-Hu-L-Myc with NotI to remove L-MYC coding sequence and religating 
using T4 ligase. The corresponding empty vector for MITF-M was constructed 
by digesting pCMV-Tag4A-MITF-M with EcoRI + HindIII and then ligating in 
an oligo made up of pCMVtag4A top and pCMVtag4A bottom. The 
corresponding empty vector for TFEB and TFE3 was constructed by digesting 
pEGFP-N1-TFEB with HindIII + KpnI and then ligating in an oligo made up by 
eGFP N1 top and eGFP N1 bottom. The MITF coding sequence 
overexpression vector used in Fig 13 was generated as follows: ApaI/EcoRI 
double digest was conducted on pCMV-Tag4A-MITF-M (wt), and ligated into 
the ApaI/EcoRI sites of pLenti-puro (pLenti-puro was a gift from Ie-Ming Shih 
[Addgene plasmid #39481]) (Guan et al., 2011). PTEN coding sequence 
overexpression vector was generated as follows: PTEN coding sequence was 
PCR amplified from pCMV Flag WT-PTEN with BamHI and EcoRI sites, the 
PCR product was double digested by BamHI and EcoRI, and ligated into the 
BamHI/EcoRI sites of pLenti-puro (pCMV Flag WT-PTEN was a gift from 
Hong Wu [Addgene plasmid #22231]) (Mosessian et al., 2009). ILEI 
overexpression vector used in Fig 12 was generated as follows: ILEI coding 
sequence was PCR amplified from a construct containing a codon optimized 
human ILEI coding sequence (unpublished; Dalton, Hussey, and Howe) with 
BamHI and NotI sites, the PCR product was double digested by BamHI and 
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NotI, and ligated into the BamHI/NotI sites of pcDNA3.1 Hygro EYFP H148Q 
(pcDNA3.1 Hygro EYFP H148Q was a gift from Peter Haggie [Addgene 
plasmid #25873]) (Galietta et al., 2001).  
ILEI reporter constructs were cloned as follows. ILEI promoter sequence 
from 2,300 base pairs upstream of the predicted transcription start site to 80 
base pairs upstream was amplified by PCR from 501-Mel genomic DNA with 5’ 
KpnI and 3’ NheI and ligated into pBV-Luc (pBV-Luc was a gift from Bert 
Vogelstein [Addgene plasmid #16539]) (He et al., 1999). Subsequent ILEI 
promoter truncation constructs were cloned by PCR using an alternate 5’ KpnI 
primer and the same 3’ NheI primer. ILEI 3’ UTR construct from stop codon to 
1,620 base pairs downstream of the stop codon was amplified by PCR from 501-
Mel cDNA (converted from total mRNA) with 5’ NheI and 3’ SalI and ligated into 
pmirGLO Dual-Luciferase (RAB14 3’ UTR WT was a gift from Curt Civin 
[Addgene plasmid # 61489]) (Kim et al., 2015).  
 
Table 2. Primer sequences.  
Primer name Sequence 
Cloning pCMVtag4A top 
AAT TCA TGA TAT CTG CGT GTC CAA 
CAC TAG TCT TAG AAT TCA CTT CAG 
CGC A 
Cloning pCMVtag4A bottom 
AAG CTT GCG CTG AAG TGA ATT CTA 
AGA CTA GTG TTG GAC ACG CAG ATA 
TCA TG 
Cloning eGFP N1 top 
AGC TTA TGA TAT CTG CGT GTC CAA 
CAC TAG TCT TAG AAT TCA CTT CAG 
CGC GGT AC 
Cloning eGFP N1 bottom CGC GCT GAA GTG AAT TCT AAG ACT AGT GTT GGA CAC GCA GAT ATC ATA 
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Primer name Sequence 
Cloning -150 KpnI ILEI 
promoter F 
GGC GGT ACC AAG TTC AGA TTG TGC 
AGC G 
Cloning -204 KpnI ILEI 
promoter F 
GGC GGT ACC ACG TGG CAA GTT 
CAG ATT 
Cloning -221 KpnI ILEI 
promoter F 
GGC GGT ACC CAT TTT TCT CCC TCC 
CGT AGI 
Cloning -300 KpnI ILEI 
promoter F 
GGC GGT ACC ATG GGAT GGG TCA 
TTT AAA ATG TTC TGC 
Cloning -2303 KpnI ILEI 
promoter F 
GGC GGT ACC GGA TTC TCC AAA TAC 
TCC ATC AGT G 
Cloning -80 NheI ILEI promoter 
R 
AAG GGC CGG AGA GCG GA 
 
SDM E-box ILEI promoter F CGG CAG CTC CCA AAT GGC AAG TTC AGA TTG TGC AGC GCC TGG C 
SDM E-box ILEI promoter R CCG CCG CAG CGG CCC TGC 
Cloning NheI ILEI 3’ UTR F ATT GCT AGC TGG AAA TGT GGA GAG AAT TGA AG 
Cloning ILEI 3’ UTR SalI R TTA GTC GAC CTG CAA CAT TTA TTT CAC AAT CCC T 
RT-PCR ACTB F ATG CTT CTA GGC GGA CTA TG 
RT-PCR ACTB R ACA AAT AAA GCC ATG CCA AT 
RT-PCR BDNF F CAA AAA GACTGCAGT GGA CA 
RT-PCR BDNF R TTG CAC TTG GTC TCG TAG AA 
RT-PCR CDH13 F GCT CAA GAT ATG GCT GGA CT 
RT-PCR CDH13 R TTG GTG AAT TTT GGT GAG TG 
RT-PCR CHOP F CAA AAT CAG AGC TGG AAC CT 
RT-PCR CHOP R CAT CTC TGC AGT TGG ATC AG 
RT-PCR DCT F CTA AGG AGG GAG GGA GAG GG 
RT-PCR DCT R GGA TTT TGC AGC CCA AGC AA 
RT-PCR FAM3C F GCA ACC AAA CTC AAT GAT GA 
RT-PCR FAM3C R ACC ACA GAA GAC CCA GTT GT 
RT-PCR FAM3C Intron F TTG CCCTAA TGC AGATCA TA 
RT-PCR FAM3C Intron R CAA CAA AGA AAC CCA CAA CA 
RT-PCR GAPDH F CTC CTC ACA GTT GCC ATG TA 
RT-PCR GAPDH R GGT TGA GCA CAG GGT ACT TT 
RT-PCR JARID1B F (Roesch et 
al., 2010) AAC AAC ATG CCA GTG ATG GA 
RT-PCR JARID1B R TAC CAG GTT TTT GGC TCA CC 
RT-PCR MITF F CTT AAA AGC ATC CGT GGA CT 
RT-PCR MITF R ACC AAA TCT GGA GAG CAG AG 
RT-PCR PMEL F GGT CCA GAT GCC AGC TCA AT 
RT-PCR PMEL R CCC AGG CAC AGG CAT GAT AA 
RT-PCR STC1 F CGT GCT GAC ATC AGA TTG TT 
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Primer name Sequence 
RT-PCR STC1 R CCG GAT TTC CAA GAG GCT AA 
RT-PCR STC2 F CCC AGA GGA AAA TAC ACA CC 
RT-PCR STC2 R GAC GCA GCT TTA CCA ATC TT 
RT-PCR TGFBR3 F CTG CAG GCT ACA CCC TTA AT 
RT-PCR TGFBR3 R TAC AGA CAA TCT GCC TTG GA 
RT-PCR USF1 F GCA CTG GTC AAT TCT TTG TG 
RT-PCR USF1 R TTC TGA CTT CGG GGA ATA AG 
RT-PCR VEGFA F CAC CAA GGC CAG CAC ATA GG 
RT-PCR VEGFA R TTT GCC CCT TTC CCT TTC CT 
RT-PCR WNT5A F AAG CAG ACG TTT CGG CTA CA 
RT-PCR WNT5A R TTT CCA ACG TCC ATC AGC GA 
RT-PCR ZEB1 F GGC GCA ATA ACG GAA AGG AAG 
RT-PCR ZEB1 R TGA GGA GAA CTG GTT GCC TG 
RT-PCR ZEB2 F CAG CTG AGG TTA TGG CTC CC 




Data on ILEI IHC comparing melanoma and breast cancer tissue was 
obtained from the Human Protein Atlas (Uhlén et al., 2005). Data on ILEI 
expression compared to MITF expression was obtained from cBioPortal (Gao et 
al., 2013). Data on ILEI expression in primary melanoma compared to metastatic 
melanoma was obtained from GEO (Barrett et al., 2013; Xu et al., 2008).  
 
ELISA 
Cells were serum starved in RPMI/0% FBS overnight, and medium was 





Cells (1 x 106, 5 ml complete medium) were seeded in 6 cm dishes. After 
24h cells were treated with DMSO vehicle or 5 µM vemurafenib (BRAFi) for 48h. 
Then, cells were harvested using trypsin and analyzed using FITC Annexin V 
Apoptosis Detection Kit I (#556547; BD Bioscience; San Jose, CA; USA).  
 
Immunoblot analysis 
Whole cell lysates were extracted as follows: 100 µL of Tris-Triton lysis 
buffer (20 mM Tris pH 7.5, 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM 
EDTA, and Halt Protease and Phosphatase Inhibitor cocktail [ThermoFisher; 
Waltham, MA; USA]) was added to a 6 well plate, cells were immediately 
scraped, incubated on ice for 30 minutes, and cleared by centrifugation for 20 
minutes at 16,000 x g. Protein concentrations were measured with Bradford 
Protein Assay (BioRad; Hercules, CA; USA). For conditioned medium 
immunoblots, cells were serum starved in RPMI/0% FBS overnight, medium was 
harvested, and precipitated using trichloroacetic acid/acetone. Protein samples 
were denatured by incubating at 95° for 5 minutes with 1x Laemmli reducing 
denaturing sample buffer (60 mM Tris-Cl pH 6.8, 1% SDS, 10% glycerol, 5% 
BME). 1 – 40 µg of whole cell lysate was resolved on an 8, 10, or 12% 
polyacrylamide SDS gel, and transferred onto PVDF membrane. Membranes 
were blocked for 1h at RT in 5% skim milk/Tris-buffered saline with 0.01% 
Tween-20 (TBST) and incubated overnight at 4° on primary antibody + 5% skim 
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milk/TBST. The following primary antibodies were used: ILEI (ab72182; Abcam; 
Cambridge, MA; USA; 1:1,000), MITF (ab12039; Abcam; Cambridge, MA; USA; 
1:1,000) a-tubulin (2144; Cell Signaling; Danvers, MA; USA; 1:10,000), Total 
AKT (4691; Cell Signaling; Danvers, MA; USA; 1:1,000), p-AKT S473 (4060; Cell 
Signaling; Danvers, MA; USA; 1:1,000), p-AKT T308 (13038; Cell Signaling; 
Danvers, MA; USA; 1:1,000), p-ERK T202/Y204 (4370; Cell Signaling; Danvers, 
MA; USA; 1:2,000), Total ERK (9120; Cell Signaling; Danvers, MA; USA; 
1:1,000), PTEN (#9188; Cell Signaling; Danvers, MA; USA; 1:1,000), LC3B 
(#2775; Cell Signaling; Danvers, MA; USA; 1:1,000), BIM (#2933; Cell Signaling; 
Danvers, MA; USA; 1:1,000), V5 (R960; ThermoFisher; Waltham, MA; USA; 
1:1,000), USF1 (C-20; sc-229; Santa Cruz; Dallas, TX; USA; 1:1,000), GAPDH 
(sc-32233; Santa Cruz; Dallas, TX; USA; 1:10,000), HSP90 (sc-13119; Santa 
Cruz; Dallas, TX; USA; 1:10,000), Ubiquitin (sc-8017; Santa Cruz; Dallas, TX; 
USA; 1:200). After primary antibody incubation, membranes were washed 4x 15 
minutes in TBST and incubated for 1h at RT on secondary antibody + TBST. The 
following secondary antibodies were used: Goat anti-Mouse IgG (31430; 
ThermoFisher; Waltham, MA; USA; 1:10,000) and Goat anti-Rabbit IgG (31460; 
ThermoFisher; Waltham, MA; USA; 1:10,000). After secondary antibody 
incubation, membranes were washed 4x 15 minutes in TBST and detected using 
Luminata Forte Western HRP substrate (EMD Millipore; Darmstadt, Germany) 
and HyBlot CL Autoradiography Film (Denville; Holliston, MA; USA) or CCD 




Lentivirus was generated by seeding 293T (1 x 106 cells; Takara Bio; 
Mountainview, CA; USA) to a 60 mm cell culture dish, and transfecting with 6 µL 
Lipofectamine 2000 (ThermoFisher; Waltham, MA; USA), 1 µg pLKO vector, 0.75 
µg psPAX2, and 0.25 µg pMD2.G. 24h post-transfection the media was changed, 
and 48 and 72h post-transfection the media was harvested. Viral supernatant 
was cleared by centrifugation, filtered through 0.22 µm filter, and stored at -80° 
until use.  
 
Luciferase analysis 
Cell lines were seeded at 5 x 104 cells per 24 well plate in 0.5 ml of 
complete medium. At 24h the cells were transfected using X-tremeGENE 9 
(Roche; Switzerland; 100 ng firefly experimental luciferase, 5 ng renilla control 
luciferase, 0.3 µl X-tremeGENE reagent, in 10 µl Opti-MEM; 200 ng experimental 
plasmid where indicated [ie – USF1 overexpression construct], 0.6µl X-
tremeGENE reagent, in 20 µl Opti-MEM). At this time the cells were treated with 
DMSO vehicle, 1 µM vemurafenib, 50 ng/ml EGF, or 5 ng/ml TGF-β. 24h post-
transfection the cells were harvested with passive lysis buffer and analyzed with 




Total RNA isolated using Trizol (Thermo Fisher Scientific; Waltham, MA; 
USA) was sent for microarray analysis at the MUSC ProteoGenomics Facility. 
Labeling was conducted using 3’ IVT Plus kit. GeneChip PrimeView Human 
Gene Expression Array was used (Affymetrix; Santa Clara, CA; USA). Data was 
analyzed using Gene Set Enrichment Analysis (GSEA) (Mootha et al., 2003; 
Subramanian et al., 2005). Heatmap was made using ClustVis (Metsalu and Vilo, 
2015). The raw data was deposited to NCBI Gene Expression Omnibus 
database under series accession number GSE95509. Fold-change was 
calculated by the average of shSCR/shILEI in both WM9 and 1205Lu cells.  
 
MTT assays 
Cells (2 x 103, 0.2 ml complete medium) were seeded in a 96 well plate. 
After 24h, cells were treated with drug as indicated. After 72h cells were treated 
for 3h with 10 µL of MTT solution (3-4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, 5 mg/ml; purchased from Sigma-Aldrich; St. Louis, 
MO; USA), and then treated for 1h with 100 µL of MTT stop solution (40% 
dimethyl formamide and 20% sodium dodecyl sulfate). Absorbance was read at 
570 nm using a Wallac plate reader.   
 
PCR analysis 
Total RNA was isolated using Trizol (Thermo Fisher Scientific; Waltham, 
MA; USA). Reverse transcription was performed using oligo dT primers and M-
MuLV Reverse Transcriptase (New England BioLabs, Ipswitch, MA; USA). Semi-
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quantitative PCR was conducted on 10 ng of cDNA using Maxima Hot Start PCR 
Master Mix (Thermo Fisher Scientific; Waltham, MA; USA). Real-time 
quantitative PCR was conducted using iQ SYBR Green Supermix (BioRad; 
Hercules, CA; USA) using CFX384 Real-Time System (BioRad; Hercules, CA; 
USA). Reactions were conducted on 50 pg - 10 ng cDNA. Primers are listed in 
S2 Table. Relative gene expression was calculated using RFX Manager software, 
and genes were normalized to GAPDH internal control.  
 
Statistical analyses 
Data are mean +/- standard deviation unless indicated otherwise. p < 0.05 
by unpaired Student’s T-test is considered significant. Representative 
experiments are repeated at least twice.  
 
Transwell invasion assays 
Cells (5 x 104, 0.1 ml in RPMI/0.1% BSA) were seeded in the upper 
chamber of a 24 well BD BioCoat Matrigel Invasion Chambers (BD Biosciences; 
San Jose, CA). 0.5 ml of complete medium was added to the lower chamber. 
After 24h, cells were fixed in methanol and stained in 0.5% crystal violet/20% 
methanol (Howley et al., 2015). 
 
Transwell migration assays 
Cells (5 x 104, 0.1 ml of RPMI/0.1% BSA) were seeded in the upper 
chamber of a 24 well Transwell Clear Polyester Membrane Inserts (Corning; 
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Corning, NY; USA). 0.5 ml of complete medium was added to the lower chamber. 
After 24h cells were fixed in 70% ethanol and stained in 0.2% crystal violet.  
 
3-D invasion assays 
Cells (5 x 103, 0.05 ml of Essential 8 Medium [Thermo Fisher Scientific; 
Waltham, MA; USA]) were seeded in a 96 well ultra-low attachment spheroid 
microplate (Corning; Corning, NY; USA). After 48h, 0.05 ml of Cultrex 3D 
Spheroid Invasion Matrix (Trevigen; Gaithersburg, MD; USA) was added and 
incubated for 1h at 37°. 0.1 ml of complete medium was layered on top of the 
invasion matrix. The spheroids were imaged after 72h using a Leica microscope, 
Amscope camera, and AmscopeX software.  
 
Wound healing assays 
Cells (3 x 105, 0.5 ml of complete medium) were seeded in a 24 well plate, 
and a 1 ml pipette tip was used to scratch the cells. Images were recorded from 0 
to 24 hours, and analyzed using ImageJ (NIH; Bethesda, MD; USA). For rescue 
experiments, 1 x106 cells were cultured in 10 cm dishes in RPMI/0.1% FBS to 
collect conditioned medium (CM). After 72h for conditioning, CM was filtered to 
remove cellular material and stored at -80°. CM was added to the cells after the 





ILEI regulates partial phenotype switching in melanoma cell lines 
 
3.1. Introduction 
EMT is a cell biological process that drives neural crest delamination 
during development, and also the acquisition of metastatic traits in cancer. While 
EMT is clearly involved in cancer progression, the exact contribution is more 
complicated than the reductionist model in which cells that undergo EMT are 
metastatic (Fischer et al., 2015; Li and Kang, 2016; Nieto et al., 2016; Zheng et 
al., 2015). There is evidence for a partial EMT or a hybrid E/M phenotype in 
which the cell blends epithelial and mesenchymal traits (Gopal et al., 2015; 
Grande et al., 2015; Grosse-Wilde et al., 2015; Jolly et al., 2016; Nieto et al., 
2016). For instance, knockdown of the EMT-transcription factor PRRX1 induces 
an epithelial morphology along with a capacity for 3-D growth, which is classically 
ascribed to mesenchymal-like cells (Ocaña et al., 2012). In another case, 
overexpression of the EMT-transcription factor YBX-1 increased the capacity for 
anoikis or suspension growth and lead to a decrease in membrane E-Cadherin, 
but did not affect motility (Gopal et al., 2015). From phenomenon such as these, 
it is clear that different traits of the EMT such as anoikis or motility can be 
uncoupled. Additionally, compared to factors activating a full EMT those 
contributing to a partial EMT are poorly defined in the literature, even though 
some suggest that the partial EMT state is the primary driver of EMT-related 
pathology (Grande et al., 2015; Grosse-Wilde et al., 2015).  
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One important detail to note is that melanoma is a malignant proliferation 
of melanocytes, a neural crest-derived cell. In the cancer context, epithelial-to-
mesenchymal transition is studied in cancers of epithelial origin (carcinomas). 
However, in the physiological development context one major cell type utilizing 
EMT is the neural crest cell. Therefore, several groups have begun studying EMT 
factors in neural crest derived tumors such as melanoma with the suspicion that 
these cell types may be hard-wired to reactivate developmental EMT pathways 
and utilize them to metastasize (Caramel et al., 2013; Denecker et al., 2014; 
Hoek and Goding, 2010). For instance, it has been shown that epithelial cells 
transformed with hTERT, SV40 large T oncoprotein, and h-RAS will become 
tumorigenic but not metastatic (Hahn et al., 1999). On the other hand, 
melanocytes transformed with the same three components will become both 
tumorigenic and metastatic, suggesting that neural crest-derived melanocytes 
possess endogenous machinery that is not possessed by epithelial cells that 
allow it to become metastatic (Gupta et al., 2005). Because melanoma is not an 
epithelial cell-derived tumor it does not undergo a classical EMT, but it does 
undergo a similar process known as phenotype switching.  
Considering that cells residing in the invasive state possess metastatic 
characteristics and can survive chemotherapy treatment, it is clear that further 
understanding of the invasive state could be applied towards improving patient 
care. Herein, we describe the contribution of ILEI to partial phenotype switching 
in MITF-low invasive melanoma cells by modulating invasion but not 





ILEI expression in melanoma 
We used the Human Protein Atlas database and found that melanoma, 
when compared to breast cancer, expressed high levels of ILEI (Fig 2A) (Uhlén 
et al., 2005). We chose to compare melanoma with breast cancer because ILEI 
has been traditionally studied in the breast cancer model. Second, we found 
using the GEO database that ILEI mRNA expression is higher in melanoma 
metastases when compared to primary tumors (Fig 2B) (Barrett et al., 2013; Xu 
et al., 2008). We confirmed these findings by conducting RT-PCR analysis of 
normal melanocytes, the poorly metastatic WM983B, and the highly metastatic 
1205Lu cell lines, and found that ILEI expression increased with aggressiveness 
(Fig 2C). As a surrogate measure for aggressiveness we have used dopachrome 
tautomerase (DCT), which is an MITF-target gene. MITF and its target genes are 
known to decrease as melanomas gain invasive capacity, and we observed an 
increase in ILEI along with a decrease in DCT. Based on these initial findings, we 
hypothesized that ILEI mRNA expression contributes to the malignant properties 
of melanoma. Of note, there are no reported regulators of ILEI mRNA expression.  
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Fig 2. ILEI expression in melanoma. A. Data from the Human Protein Atlas 
showing IHC stain intensity for ILEI in melanoma vs breast cancer (Uhlén et al., 
2005). B. Data from NCBI GEO database (Xu et al., 2008) comparing ILEI mRNA 
levels in primary vs metastatic melanoma patient samples, accession GSE8401, 
Nprimary = 31, Nmetastatic = 52, meanprimary = 136, meanmetastatic = 323, SDprimary = 63, 
SDmetastatic = 208, p = 5 x 10-6 by unpaired Student’s t-test (Xu et al., 2008). C. 
Semi-quantitative RT-PCR analysis of ILEI and DCT in primary epidermal 
melanocytes, WM983, and 1205Lu cells.  
 
We characterized the specificity of the ILEI antibody (Abcam, ab72182) by 
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Fig 1. ILEI expression in melanoma.  








































p = 5 x 10-6 
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form of ILEI ran as a doublet between 20 and 25 kDa but presented with many 
non-specific bands (Fig 3A). The antibody was also tested on IHC using mouse 
tissue and immunoprecipitation of the native ILEI, but no positive signal was 
detected in either case (data not shown).  
 
Fig 3. Validation of ab72182, rabbit a ILEI. A. Immunoblot analysis of ILEI-
low 501-Mel expressing shSCR, shILEI 3, or shILEI 5. 
 
We used immunoblot, PCR, and ELISA analysis ILEI expression in a 
panel of melanoma cell lines and observed two distinct populations of cells either 
expressing low (ILEI-low) or high (ILEI-high) levels of ILEI (Fig 4A-C). We noted 
that the ILEI-low population correlated with the MITF-high proliferative cells 




















whereas the ILEI-high population correlated with the MITF-low invasive cell lines 
(Fig 4A-C). Further, we used TCGA RNA-seq data from cBioPortal to confirm the 
negative correlation (Pearson’s correlation coefficient: r = -0.217, N = 471, p = 
1.94 x 10-6) between ILEI and MITF in melanoma patient samples (Fig 3D) 
(Cancer Genome Atlas, 2015; Cerami et al., 2012; Gao et al., 2013). Based on 
these initial findings, we hypothesized that ILEI contributes to the biology of 
MITF-low melanoma cells.  
 
Fig 2. ILEI expression in melanoma cell lines.  
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Fig 4. ILEI expression in melanoma cell lines. A. Immunoblot and semi-
quantitative RT-PCR analysis of ILEI and MITF levels in WM3912, WM983B, 
501-Mel, Sk-Mel-28, WM793, 1205Lu, and WM9 cells. IB WCL indicates ILEI in 
the whole cell lysate, whereas IB CM indicates ILEI in protein that was 
precipitated out of serum-free conditioned medium. B. Quantitative RT-PCR 
analysis of MITF and ILEI levels in WM3912, 501-Mel, 1205Lu, and WM9 cells. 
Grey bars indicate MITF mRNA and black bars indicate ILEI mRNA. N = 3, mean 
+/- SD, transcript levels normalized to GAPDH. C. ILEI ELISA of conditioned 
medium from WM3912, WM983B, 501-Mel, Sk-Mel-28, WM793, and 1205Lu 
cells. Prior to conditioned medium analysis, the cells were cultured for 24h in 
serum-free RPMI. D. Melanoma patient RNA-seq data from cBioPortal (Cerami 
et al., 2012; Gao et al., 2013) showing MITF mRNA z-score vs FAM3C mRNA z-
score in melanoma patient samples. The correlation was calculated using 
Pearson’s correlation coefficient: r = -0.217, N = 471, p = 1.94 x 10-6.   
 
The effect of ILEI modulation on phenotype switching.  
In order to assess the contribution of ILEI to phenotype switching we 
chose to investigate two well-described characteristics of phenotype switching; 
namely, invasion and chemoresistance (Eichhoff et al., 2011; Goodall et al., 
2008; Hoek et al., 2008; Hoek et al., 2006; Javelaud et al., 2011; Ramsdale et al., 
2015; Richard et al., 2016). Our results indicate that MITF-low cells have high 
ILEI expression, so we started by confirming that the ILEI-high cells used in this 
study are more invasive than the ILEI-low cells. We used both 3-D invasion and 
transwell migration assays to qualitatively confirm that our ILEI-high cells are 
more invasive than ILEI-low cells (Fig 5A-B). Next, we generated ILEI knockdown 
cells to test invasive potential in vitro. We used several techniques (wound 
healing, transwell migration, and transwell invasion) and found that ILEI 
knockdown attenuates migration/invasion by (Fig 5C-F, Table 3).  
Table 3. The effect of ILEI knockdown on invasive potential.   





















1 0.584 ±0.084 
0.457 
±0.120 - - 
Values represent mean ± standard deviation. n = 3.  
We confirmed these results with the following control experiments: ILEI 
immunoblot to test the extent of the knockdown, and proliferation rate, which can 
confound migration/invasion experiments. In both experiments we saw the 
expected result that ILEI was indeed knocked down, and that ILEI knockdown did 
not affect the proliferation rate (Fig 5G-H).  
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Fig 5. The effect of ILEI knockdown on invasive potential and proliferation. 
A. 3-D spheroid invasion assay of ILEI-low WM983B or ILEI-high WM9 cells in 
extracellular matrix. B. Transwell migration assay of ILEI-low 501-Mel or ILEI-
high WM9 cells. Images are pseudo colored blue. C. Wound healing assay of 
1205Lu or WM9 expressing shSCR, shILEI 3, or shILEI 5. Images shown are 
representative of three independently seeded replicates. D. Quantification of 
panel E using ImageJ software. N = 3, mean +/- SEM, and * indicates p < 0.05 by 






































































Fig 4. The effect of ILEI knockdown in ILEI-high/MITF-low cells on invasion and proliferation.  
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and white bars indicate shILEI 5. E. Transwell migration assay of 1205Lu or 
WM9 expressing shSCR, shILEI 3, or shILEI 5. N = 3, mean +/- SEM, and * 
indicates p < 0.05 by unpaired Student’s t-test. F. Transwell invasion assay of 
1205Lu expressing shSCR, shILEI 3, or shILEI 5. N = 3, mean +/- SEM, and * 
indicates p < 0.05 by unpaired Student’s t-test. Images are representative of 
three independently seeded replicates, and pseudo colored in blue.  G. 
Immunoblot analysis of ILEI-high 1205Lu or WM9 expressing shSCR, shILEI 3, 
or shILEI 5. H. Cell counts of 1205Lu or WM9 expressing shSCR or shILEI 3. 
Solid lines indicate shSCR and dotted lines indicate shILEI 3. Data is 
representative of three independently seeded replicates. 
 
Considering that ILEI is a secreted cytokine, we wanted to see if the 
conditioned medium (CM) from ILEI expressing 1205Lu shSCR cells could 
rescue the migration phenotype in ILEI knockdown 1205Lu shILEI cells. Thus, 
we conducted wound healing assays with 1205Lu shSCR or shILEI cells in the 
presence of CM from 1205Lu shSCR or shILEI cells (Fig 6A). We found that 
wound healing of ILEI knockdown cells was not rescued by ILEI expressing CM. 
Unpublished data from our lab suggests that ILEI binds to and activates the 
leukemia-inhibitory factor receptor (LIFR), and we have also seen that ILEI 
positively regulates LIFR (Dalton, Woosley, Hussey, and Howe, unpublished; Fig 
6B). Therefore, we hypothesize that 1205Lu shILEI cells are unresponsive to ILEI 
expressing CM because they have downregulated the ILEI receptor. In support of 
this, when we treat ILEI expressing 1205Lu shSCR cells with ILEI expressing CM 
we see more wound healing than with shILEI CM. This finding is consistent with 
1205Lu shSCR expressing LIFR, and retaining ILEI responsiveness (Fig 6B).  
	 43	
 
Fig 6. The effect of 1205Lu conditioned medium (CM) replacement on 
wound healing. A. Wound healing assay of 1205Lu cells expressing shSCR or 
shILEI 3. CM was replaced with serum-free conditioned medium from either 
shSCR or shILEI 3, and incubated for 24h during wound healing. N = 3, mean +/- 
SEM, and p-value as indicated by unpaired Student’s t-test compared to shSCR 
cells and shSCR conditioned medium. B. Immunoblot or PCR analysis of 1205Lu 
cells expressing shSCR or shILEI 3. 
 
Next, the capacity of these cells to invade in vivo was tested with a mouse 
xenograft model. Both flank injections and tail vein injections were conducted 
using 1205Lu cells expressing shSCR or shILEI 3. For flank injections, mice were 
sacrificed after 4 weeks of tumor growth and found no difference in primary tumor 
size (Fig 7A-B). Histopathological analysis of lungs were conducted to look for 
spontaneous metastases but only one metastasis was detected in a mouse 
injected with 1205Lu shILEI 3 cells (data not shown). For tail vein injections, mice 
were sacrificed mice after 8 weeks of lung colonization and found that 1205Lu 
shSCR cells colonized the lung more efficiently than the 1205Lu shILEI 3 cells 
(Fig 7C-D). From these data it was concluded that ILEI knockdown in MITF-
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formation. Based on these data no firm conclusions can be drawn regarding the 
contribution of ILEI to spontaneous metastases.  
 
Fig 7. The effect of ILEI knockdown on in vivo tumorigenesis. A. Flank 
injection of 1205Lu cells expressing shSCR or shILEI 3. N = 5, bar indicates 
mean, n.s. indicates p > 0.05 by Student’s t-test as compared to shSCR. B. 
Primary tumors from flank injection experiments. C. Tail vein injection of 1205Lu 
cells expressing shSCR or shILEI 3. N = 9 for shSCR and 7 for shILEI 3, bar 
indicates mean, p-value indicated by Student’s t-test as compared to shSCR. D. 
Representative images of lung nodules from either shSCR or shILEI 3.  
 
 
In addition to invasion, MITF is also associated with chemoresistance and 
it has been shown that: 1) Cell lines that are more intrinsically resistant to 
vemurafenib (BRAFi) are MITF-low, and 2) Long-term treatment of cell lines with 
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2014; Saez-Ayala et al., 2013). Thus, we postulated that ILEI knockdown would 
decrease chemoresistance or that ILEI expression would increase upon 
acquisition of resistance. First, we confirmed that our MITF-low ILEI-high cells 
have higher intrinsic resistance to vemurafenib by treating cells with vemurafenib 
and conducting immunoblot analysis for the apoptosis marker BIM, MTT, or 
clonogenic assay (Fig 8A-C). Next, we used our ILEI knockdown cells and found 
that ILEI knockdown has a subtle effect on BIM induction and cell survival as 
measured by MTT assay, but has no effect on cell survival as measured by 
clonogenic assay or FACS analysis for the apoptosis markers Annexin V and PI 
(Fig 8D-G). While BIM is just one marker of apoptosis, and vemurafenib is known 
to have effects on cell cycle progression and autophagy, we conclude based on 
the minor results in the MTT and clonogenic assays that ILEI knockdown does 
not affect the response to vemurafenib.  
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Fig 8. The effect of ILEI knockdown on chemoresistance. A. Immunoblot 
analysis of ERK and BIM levels in 501-Mel or 1205Lu cells treated with 
vemurafenib (BRAFi, 24h, 1 μM). EL indicates the extra-long isoform of BIM. 
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1205Lu cells treated with vemurafenib (0 up to 10 μM, 4d). Dotted lines 
indicate ILEI-high cells and solid lines indicate ILEI-low cells. C. Clonogenic 
survival assay of WM3912, WM983B, WM793, or 1205Lu cells treated with 
vemurafenib (10 μM). D. Immunoblot analysis of ERK, ILEI, and BIM levels in 
ILEI-high 1205Lu expressing shSCR or shILEI 3. Cells were treated with 
vemurafenib (24h; 1 μM). EL indicates extra-long isoform of BIM. E. MTT 
analysis of 1205Lu expressing shSCR or shILEI 3 treated with vemurafenib 
(72h, 0 up to 50 μM). Solid lines indicate shSCR and dashed lines indicate 
shILEI 3. N = 3, mean +/- SD, * indicates p < 0.05 by unpaired Student’s t-test. 
F. Clonogenic survival assay of 1205Lu expressing shSCR or shILEI 3 
treated with vemurafenib (7 days, 1 μM). Images are representative of five 
independently seeded experiments. G. FACS analysis of 1205Lu expressing 
shSCR or shILEI 3 treated with vemurafenib (48h, 5 μM). Solid bars indicate 
Annexin V-FITC low and PI low cells, checkered bars indicate Annexin V-
FITC low and PI high cells, hatched bars indicate Annexin V-FITC high and PI 
low cells, and white bars indicate Annexin V-FITC high and PI high cells. N = 
3, mean +/- SD, n.s. indicates p > 0.05 by unpaired Student’s t-test.  
 
An alternate possibility for ILEI contribution to chemoresistance is that 
long-term treatment of melanoma cells with vemurafenib would generate 
vemurafenib resistant cell lines with increased expression of ILEI. We generated 
vemurafenib resistant cell lines according to established protocols (Girotti et al., 
2013; Yoshida et al., 2016). Briefly, melanoma cell lines were treated with 
increasing concentrations of vemurafenib up to 10 µM for up to two months in 
order to generate stably vemurafenib-resistant clones. We confirmed that our 
cells were resistant to vemurafenib by treating either parent or long-term 
vemurafenib treated resistant cells with vemurafenib and measuring the induction 
of BIM (Fig 9A). According to our expectation vemurafenib-induced BIM was 
attenuated in the resistant cells, but to our surprise ILEI expression was either 
unaffected or decreased upon acquisition of resistance. We noted that ILEI 
expression correlated with phospho-ERK levels, and this will be addressed in 
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Chapter 4. From these studies, we conclude that ILEI knockdown decreases 
invasive potential but does not affect chemoresistance.  
 
Fig 9. The effect of acquired vemurafenib resistance on ILEI expression. 
A. Immunoblot analysis of parental Sk-Mel-28 or WM983B cells or those with 
acquired vemurafenib (BRAFi) resistance were treated with vemurafenib (24h, 
0 up to 5 μM).  
 
 Considering the effect of ILEI knockdown on ILEI-high cells, we also 
wanted to know the effect of ILEI overexpression on ILEI-low cells. We generated 
MITF-high ILEI-low cells that overexpressed ILEI as seen by immunoblot of 
either the whole cell lysate or the conditioned medium (Fig 10A). Next, we tested 
the effects of ILEI overexpression on phenotype switching. We found that ILEI 
overexpression did not affect proliferation rate or wound healing (Fig 10B-C). 
While we observed a subtle effect of ILEI overexpression repressing 
vemurafenib-induced BIM induction, we saw by MTT assay that the survival of 
ILEI low
Sk-Mel-28 WM983B
Parent Resistant Parent Resistant
Vem









the cells was unaffected (Fig 10D-E).  From these studies we conclude that ILEI 
overexpression does not affect phenotype switching, and that ILEI is necessary 
but not sufficient to induce the invasive state. These results are consistent with 
the 1205Lu shSCR and shILEI CM swap experiments in which CM from 1205Lu 
shSCR only affected 1205Lu shSCR cells and not 1205Lu shILEI cells (Fig 6A). 
We believe this is because ILEI upregulates its own receptor, LIFR, so additional 
cofactors must be regulated along with ILEI to induce the invasive state.  Another 
possibility is that the C terminal V5 tag renders the ILEI inactive. Considering that 
C terminal V5 tagged ILEI is secreted into the conditioned medium, we speculate 
that this ILEI is functional. However, considering we do not have a readout for 
ILEI overexpression we cannot reach a firm conclusion regarding the activity of C 
terminal V5-tagged ILEI.  
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Fig 10. The effect of ILEI overexpression in ILEI-low/MITF-high cells on 
proliferation, migration, and chemoresistance. A. Immunoblot analysis of 
ILEI and V5 of ILEI-low Sk-Mel-28 or 501-Mel cells stably overexpressing a C 
terminal V5-tagged ILEI construct. B. Cell counts of Sk-Mel-28 or 501-Mel 






















































































































cells expressing vector or ILEI. Solid lines indicate vector and dotted lines 
indicate ILEI. Data is representative of two independently seeded replicates. 
C. Wound healing assay of Sk-Mel-28 or 501-Mel cells expressing vector or 
ILEI. Images shown are representative of three independently seeded 
replicates. D. Quantification of panel C using ImageJ software. N = 3, mean 
+/- SEM, and * indicates p < 0.05 by unpaired Student’s t-test. Black bars 
indicate vector and white bars indicate ILEI. E. Immunoblot analysis of ERK, 
ILEI, and BIM levels in 501-Mel cells stably transduced with vector or ILEI. 
Cells were treated with vemurafenib (24h; 1 μM). EL indicates extra-long 
isoform of BIM. F. MTT analysis of 501-Mel cells expressing vector or ILEI 
treated with vemurafenib (72h, 0 up to 50 μM). Solid lines indicate vector and 
dotted lines indicate ILE. N = 3, mean +/- SD, * indicates p < 0.05 by unpaired 
Student’s t-test.  
 
The effect of ILEI modulation on gene expression.  
Since we observed a biological effect of ILEI knockdown in MITF-low ILEI-
high cells we concluded that ILEI was functional in these cells, and thus we 
conducted gene expression analysis on these cells to elucidate the molecular 
mechanism(s) of ILEI-modulated invasion. We conducted microarray analysis on 
two ILEI-high cell lines 1205Lu and WM9, stably transduced with shSCR, shILEI 
3, shILEI 4, or shILEI 5. Analysis of genes commonly regulated in both cell lines 
across all shRNA hairpins revealed a set of 137 genes up-regulated in shSCR vs 
shILEI and 64 genes upregulated in shILEI vs shSCR (Fig 11A). The top 
regulated genes included many that are involved in phenotype switching 
including CDH13, HIF-2a, and BDNF (Fig 11B; Table 4 and 5) (Widmer et al., 
2012). Interestingly, other well-characterized markers of phenotype switching 
including MITF and its downstream targets MAGEA1, TYR, and PMEL, EMT 
transcription factors like ZEB1 and ZEB2, and invasive phenotype markers like 
WNT5A, AXL, and NGFR were not regulated across both cell lines (Fig 12A). 
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These genes are all known to be regulated at the mRNA level during phenotype 
switching. We conducted gene set enrichment analysis on the genes that were 
up in shSCR vs shILEI and observed enrichment of genes regulated by hypoxia, 
mTOR signaling, and UPR, as well as JUN and NFAT transcription factor motifs, 
which are known to regulate the invasive phenotype (Fig 11C) (Mootha et al., 
2003; Subramanian et al., 2005). Genes that were down in shSCR vs shILEI 
were not enriched for any gene sets (data not shown). Overall these data 
suggest that knockdown of ILEI in ILEI-high cells regulates the expression of 
genes that are important to the invasive MITF-low phenotype.  
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Fig 11. The effect of ILEI knockdown on gene expression. A. Microarray 
analysis of ILEI-high 1205Lu or WM9 stably expressing shSCR, shILEI 3, shILEI 
4, or shILEI 5. Venn diagrams represent numbers of genes up (1.2-fold) or down 
(0.8-fold) in shSCR vs shILEI (p < 0.05 in shSCR vs shILEI sample by unpaired 
Student’s t-test, N = 3). B. Heat map of top 10 genes up or down in shSCR vs 
shILEI (p < 0.05 in shSCR vs shILEI by unpaired Student’s t-test, N=3). Heat 
map was generated using ClustVis (Metsalu and Vilo, 2015). C. Gene set 
b
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enrichment analysis (Mootha et al., 2003; Subramanian et al., 2005) of genes up 
in shSCR vs shILEI (>1.2-fold and p < 0.05; 137 genes). Enriched hallmark 
pathways and transcription factor motifs are shown.  
 
Fig 12. The effect of ILEI knockdown on phenotype switch markers. A. Heat 
map of genes representative of the proliferative or invasive phenotype. Heat map 
was generated using ClustVis (Metsalu and Vilo, 2015). 
 
Table 4. Genes up in shSCR vs shILEI. All genes are significantly up in shSCR 
vs shILEI (1.5-fold, p < 0.05 by unpaired Student’s t-test) in both 1205Lu and 
WM9 cells.  
Gene Title Gene Symbol Fold-change 
Chromosome 15 open reading frame 48 C15orf48 3.70 
Stanniocalcin 2 STC2 2.78 
Ferritin, heavy polypeptide 1 FTH1 2.52 
Aldo-keto reductase family 1, member B1 AKR1B1 2.37 
Heme oxygenase (decycling) 1 HMOX1 2.14 
Endothelial PAS domain protein 1 (HIF-2𝛂) EPAS1 2.11 
Sterile alpha motif domain containing 9-like SAMD9L 2.11 
Laminin, beta 3 LAMB3 2.05 
Ankyrin repeat domain 29 ANKRD29 1.90 




















































































































































































Transmembrane protein 200A TMEM200A 1.86 
Leucine rich adaptor protein 1-like LURAP1L 1.84 
DNA-damage-inducible transcript 3 (CHOP) DDIT3 1.83 
Adenosine monophosphate deaminase 3 AMPD3 1.80 
Solute carrier family 38, member 1 SLC38A1 1.78 
Lysine (K)-specific demethylase 5B (JARID1B) KDM5B 1.77 
Brain-derived neurotrophic factor BDNF 1.76 
Laccase (multicopper oxidoreductase) domain 
containing 1 LACC1 1.67 
  RFTN1 1.67 
Nuclear receptor coactivator 3 NCOA3 1.65 
Nuclear receptor coactivator 7 NCOA7 1.63 
Tetratricopeptide repeat domain 17 TTC17 1.61 
Vascular endothelial growth factor A VEGFA 1.56 
Aldo-keto reductase family 1, member B10 (aldose 
reductase) AKR1B10 1.52 
ERO1-like beta (S. cerevisiae) ERO1LB 1.52 
Glutamate-cysteine ligase, modifier subunit GCLM 1.51 
Thioredoxin reductase 1 TXNRD1 1.51 
Adaptor-related protein complex 2, alpha 2 subunit AP2A2 1.51 
Interleukin 31 receptor A IL31RA 1.50 
 
Table 5. Genes down in shSCR vs shILEI. All genes are significantly down in 
shSCR vs shILEI (0.66-fold, p < 0.05 by unpaired Student’s t-test) in both 1205Lu 
and WM9 cells.  
Gene Title Gene Symbol Fold-change 
Peroxiredoxin 1 PRDX1 0.08 
Zinc finger protein 367 ZNF367 0.39 
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Solute carrier family 9, subfamily A SLC9A6 0.44 
SHC (Src homology 2 domain containing) family, 
member 4 SHC4 0.46 
Fc receptor-like A FCRLA 0.54 
Transforming growth factor, beta receptor III TGFBR3 0.57 
Growth arrest-specific 7 GAS7 0.58 
Exostoses (multiple)-like 1 EXTL1 0.59 
Atlastin GTPase 3 ATL3 0.60 
Fc receptor-like A FCRLA 0.60 
MAS-related GPR, member X3 MRGPRX3 0.62 
SRY (sex determining region Y)-box 2 SOX2 0.64 
 
 In particular, we were interested in the following four genes: 1) Lysine 
demethylase 5B (JARID1B), a known marker of melanoma stem cells (Roesch et 
al., 2010; Roesch et al., 2013), 2) Brain-derived neurotrophic factor (BDNF), a 
ligand for the melanoma initiating cell marker p75 NGFR (Boiko et al., 2010; 
Civenni et al., 2011; Redmer et al., 2014), 3) CHOP (DNA damage-inducible 
transcript 3, DDIT3), a marker for ER stress, which is activated during EMT 
(Feng et al., 2014), and 4) TGF-b receptor III (TGFBR3, b-glycan), a TGF-b 
signaling co-receptor that has dual roles in activating and inhibiting TGF-b 
signaling (Gatza et al., 2010). We used two ILEI-high (1205Lu and WM9) cell 
models to confirm these genes of interest by semi-quantitative and real-time 
quantitative PCR (Fig 13A-B). We successfully validated JARID1B and BDNF, 
which are the most robust ILEI target genes. We saw CHOP validate in the 
qPCR but not the semi-qPCR, whereas we saw TGFBR3 validate in the semi-
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qPCR but not the qPCR. Finally, we failed to validate several markers of the 
invasive phenotype that were suggested to be regulated on the microarray. 
These included VEGFA, CDH13, WNT5A, and STC (Fig 13B or data not shown).   
 
Fig 13. Confirmation of array data. A. Semi-quantitative RT-PCR analysis of 
1205Lu, WM9, 501-Mel, or Sk-Mel-28 cells expressing shSCR, shILEI3, or 
shILEI 5 as indicated. B. Real-time quantitative PCR analysis of 1205Lu cells 
expressing shSCR or shILEI 3. N = 3, mean, +/- SD, * indicates p<0.05 by 
unpaired Student’s t-test as compared to shSCR. Genes are ranked by 
significance as assessed by unpaired Student’s t-test, with ILEI having the 
highest significance. Transcript levels are normalized to GAPDH. 
 
 Previously, we treated 1205Lu shSCR or shILEI cells with CM from 
1205Lu shSCR or shILEI cells to see if shSCR CM could rescue the effect of ILEI 
knockdown on wound healing (Fig 6). While we found that 1205Lu shSCR CM 
could not rescue the effects of ILEI knockdown on wound healing, we considered 
the possibility that exogenous ILEI could rescue the expression of genes 
modulated by ILEI knockdown without affecting the biological phenotype. We 
found that treatment of 1205Lu shILEI cells with CM from either 1205Lu shSCR 


































We also conducted ILEI overexpression (ILEI coding sequence with no tag) in 
1205Lu shSCR or shILEI and reached a similar finding (Fig 14B). This is 
consistent with the idea that ILEI upregulates the expression of its own receptor, 
LIFR, thus leaving shILEI cells unresponsive to ILEI (Fig 6B).  
 
Fig 14. The effect of 1205Lu conditioned medium (CM) replacement or ILEI 
overexpression on ILEI target gene expression. A. Semi-quantitative RT-PCR 
analysis of 1205Lu cells expressing shSCR or shILEI 3 after 24h incubation with 
CM from 1205Lu cells expressing shSCR or shILEI 3. B. Semi-quantitative RT-
PCR analysis of 1205Lu cells expressing shSCR or shILEI 3, with additional 
transient overexpression with YFP vector control or ILEI overexpression 




Classical EMT factors are increasingly gaining recognition as regulators of 
neural crest-derived tumors such as melanoma. Herein we characterize the 
EMT-inducing cytokine ILEI in melanoma. We found that ILEI is highly expressed 
in MITF-low invasive melanoma cells, and that ILEI knockdown in MITF-low cells 
attenuates invasive potential but does not affect MITF expression, or 
chemoresistance. We conducted gene expression analysis and show that ILEI 
regulates genes that are important to the MITF-low invasive phenotype.  
With regards to phenotype switching and EMT, we offer the following 
discussion. EMT/phenotype switching encompasses a vast range of phenotypes 
including motility, resistance to apoptosis, and self-renewal and it is becoming 
increasingly clear that EMT is not a simple on/off switch but a long gradient with 
multiple paths between the epithelial and mesenchymal states. Consistent with 
this sort of gradient within EMT, there must be EMT factors that induce parts but 
not all of the EMT-phenotype (Gopal et al., 2015; Grande et al., 2015; Ocaña et 
al., 2012). There is obvious clinical relevance to this nuance given the evidence 
that the partial EMT state represents a more aggressive state of the tumor 
(Grosse-Wilde et al., 2015; Jolly et al., 2016; Nieto et al., 2016). However, in the 
field of melanoma and phenotype switching there has not been a clear 
identification of factors involved in a partial phenotype switch. Previous gene 
expression analyses on patient samples or cell lines that define the phenotype 
switch identify a proliferative phenotype and an invasive phenotype, but the data 
also contain an overlooked intermediate state in-between the proliferative and 
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invasive phenotypes (Hoek et al., 2006; Verfaillie et al., 2015). More recently, 
single-cell gene expression analyses have confirmed the presence of wide 
heterogeneity within a cell line or a tumor sample that is broadly categorized as 
proliferative or invasive (Ennen et al., 2015; Tirosh et al., 2016). Additionally, 
circulating tumor cell (CTC) studies have shown that melanoma CTCs express 
MITF, suggesting that the expression of MITF cannot be considered an absolute 
indicator of phenotype switching status, and that phenotype switching has further 
layers of complexity in addition to its major regulator, MITF (Koyanagi et al., 
2006; Ramskold et al., 2012).  
Based on the results of this study we speculate that ILEI contributes to a 
partial phenotype switch by modulating invasive potential but not 
chemoresistance or MITF expression in MITF-low invasive cells (Fig 5, 7, 8, 10, 
12).  
The finding that ILEI contributes to partial phenotype switching is 
important because therapeutic targeting of phenotype switching will require the 
fine dissection of its multiple molecular components. For instance in the case of 
ILEI, one could imagine a therapeutic scenario in which inhibition of ILEI would 
shift the cells to an intermediate state with decreased metastatic potential and an 
unchanged proliferative rate whereas a broad inhibitor of the invasive state would 
shift the cells to a proliferative state with decreased metastatic potential and 
increased proliferative rate.  
We believe new models could benefit the ILEI field, considering that the 
molecular details of ILEI-induced EMT have been elusive (Zhu et al., 2002). The 
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receptor for ILEI is yet to be reported, and though ILEI has been described to 
activate STAT and ERK signaling, the evidence is inconsistent. ILEI undergoes 
post-translational processing, and it seems that the cellular context is critical for 
the elucidation of details relevant to ILEI (Csiszar et al., 2014). Therefore, given a 
clear role for ILEI in our ILEI-high MITF-low cells, we conducted gene expression 
analyses hoping to garner clues towards the molecular mechanism of ILEI-
induced invasion (Fig 11). In the GSEA comparing shSCR vs shILEI we found 
several intriguing hits. Among the Hallmark Pathways, we were particularly 
interested in the AKT, UPR, and Interferon response. We were intrigued to see 
AKT/mTOR in the gene set enrichment analysis as ILEI has been shown to 
activate AKT signaling in a mouse diabetes model (Chen et al., 2017). Another 
interesting hit was UPR, which was confirmed by the validation of the ER-stress 
marker CHOP (Fig 13). ER stress has been shown to be overactive in 
mesenchymal-like cells, and that cells that have undergone an EMT have 
increased sensitivity to ER stress inducers (Feng et al., 2014). Future studies will 
determine if modulation of ILEI affects ER stress sensitivity. It will be interesting 
to know if ILEI directly regulates ER stress or if the upregulation of CHOP is a 
result of the EMT-like phenotype that is induced by ILEI. A third notable hit from 
our gene expression analysis is interferon response. This caught our attention for 
two reasons. The first is technical; shRNA gene expression analyses are 
commonly fraught with the non-specific activation of viral response genes (Bridge 
et al., 2003). This occurs because shRNA is double stranded RNA, which 
activates Toll-like receptors to induce interferons (Kariko et al., 2004). While our 
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experiments included controls including scrambled shRNA, three different shRNA 
sequences targeting ILEI, and two different cell lines, we cannot rule out the 
possibility of a non-specific response. A second reason we noticed interferon 
response in the gene set enrichment analysis is because ILEI is a secreted 
cytokine-like molecule, and while the evidence described in this dissertation 
suggests that ILEI plays an autocrine tumor cell function, an alluring alternative is 
that ILEI can act in a paracrine manner to regulate the tumor infiltrating immune 
system. Future studies will explore the role of ILEI in the immune system. In 
particular, we believe that ILEI may act as a positive regulator of SMAD signaling 
by downregulating TGFBR3 (Fig 13). It has been shown previously that TGFBR3 
inhibits SMAD signaling to inhibit the tumor suppressive immune system (Hanks 
et al., 2013). Thus, one could imagine a situation in which tumor intrinsic ILEI 
expression downregulates TGFBR3, upregulates SMAD signaling, 
downregulates the tumor suppressive immune system, and thus promotes 
immune evasion and tumor progression. Finally, there were also several 
interesting hits among the transcription factor motifs enriched in shSCR vs shILEI. 
The most enriched TF motif is JUN, which has recently been established as a 
major regulator of the invasive phenotype (Ramsdale et al., 2015; Riesenberg et 
al., 2015; Verfaillie et al., 2015).  
It is notable that either ILEI overexpression or the addition of conditioned 
medium (CM) from ILEI-high 1205Lu shSCR cells did not rescue the wound 
healing ability or the gene expression of ILEI target genes in 1205Lu shILEI cells 
(Fig 7, 13). Additionally, ILEI overexpression in ILEI-low Sk-Mel-28 or 501-Mel 
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cells did not affect their biological phenotype (Fig 8). Based on these findings we 
conclude that ILEI is necessary but not sufficient to induce the invasive 
phenotype. Based on our findings that ILEI knockdown results in decreased LIFR, 
and using unpublished data from our research group that shows LIFR is the ILEI 
receptor, we can speculate that ILEI requires the expression of LIFR, and 
possibly other co-factors, to drive the invasive phenotype (Fig 6B; Dalton, 
Woosley, Hussey, Howe; unpublished).  
 We have shown here that: 1) ILEI expression increases during melanoma 
progression, 2) ILEI expression inversely correlates with MITF expression, 3) 
Knockdown of ILEI attenuates invasive potential but not chemoresistance or 
MITF expression, and 4) Knockdown of ILEI attenuates JUN signaling. Based on 
these findings we conclude that ILEI regulates partial phenotype switching in 




Phenotype switching regulates ILEI in melanoma cell lines 
 
4.1. Introduction 
Phenotype switching is a phenomenon that was originally described based 
on gene expression data, which revealed that the transcriptomes of melanoma 
cell lines (Hoek et al., 2006; Widmer et al., 2012) and patient samples (Verfaillie 
et al., 2015) could be separated into distinct proliferative and invasive states. 
These two states are most often identified by the master melanocyte lineage 
regulator MITF (micropthalmia-related transcription factor) with the proliferative 
state expressing high MITF while the invasive state expresses low MITF. In 
addition to the finding that melanoma cells could be classified by these two 
descriptors, several groups have described that melanoma cells can reversibly 
switch between these two subsets. Hoek et al described that the phenotype 
switch can occur in vivo by injecting a pure proliferative cell population into mice 
as a xenograft, and then observing the presence of both proliferative and 
invasive cells. The same was true using a pure invasive cell population. From 
these studies Hoek concluded thatt some component of the tumor 
microenvironment is driving this phenotype switch (Hoek et al., 2008). This was 
followed up by papers that described phenotype switching either by direct genetic 
manipulation of MITF or environmental cues like TGF-b, inflammation, and 
hypoxia (Carreira et al., 2006; Cheli et al., 2012; Hoek et al., 2008; Saez-Ayala et 
al., 2013; Yang et al., 2008).  
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The various environmental regulators of phenotype switching all 
converge on regulation of MITF. For instance, MITF is regulated by the MAPK 
signaling pathway, which has been shown to inhibit MITF expression by 
inducing proteasomal degradation (Wu et al., 2000). Thus, MAPK inhibitors 
such as vemurafenib upregulate MITF expression to promote the proliferative 
phenotype (Caramel et al., 2013; Haq et al., 2013). On the other hand, the 
invasive phenotype can be induced by cytokines such as TGF-b that inhibit 
MITF expression (Pierrat et al., 2012).  
In addition to MITF, other transcription factors such as upstream 
stimulating factor (USF) contribute to the melanoma response to 
environmental stress. USF is a member of the basic/helix-loop-helix/leucine 
zipper family that binds to both E-box (CACGTG) and pyrimidine rich initiator 
sequences (Ferre-D'Amare et al., 1994; Roy et al., 1991; Yamanaka et al., 
2016). It is known to heterodimerze with the AP-1/JUN co-factor FRA1, as 
well as the general transcription factor GTF2I (Pognonec et al., 1997; Roy et 
al., 1997). In the case of pigmentation, whereas MITF is involved in 
constitutive pigmentation, USF is involved in UV-mediated tanning. 
Mechanistically, UV light activates p38 MAPK to phosphorylate USF at 
threonine 153, which increases its transcriptional activation of pigmentation 
genes (Galibert et al., 2001). It was further shown that this phosphorylation 
primes USF to be acetylated at lysine 199, and that this acetylation acts as a 
negative feedback regulator to inhibit its transcription activity (Corre et al., 
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2009). The best-known contribution of USF to biology is its role in metabolic 
diseases. For instance, a single nucleotide polymorphism (SNP) in a non-
coding region of USF1 is linked to familial combined hyperlipidemia (FCHL), 
which is a genetic disease resulting in elevated cholesterol levels and early 
onset coronary heart disease (Pajukanta et al., 2004). In addition, multiple 
studies have shown a linkage between the same USF1 SNP and type II 
diabetes (Holzapfel et al., 2008; Meex et al., 2008). Accordingly, a mouse 
model of transgenic overexpression of USF1 induced obesity and increased 
blood glucose levels, which are suggestive of metabolic syndrome (Wu et al., 
2010). On the other hand, a mouse model of USF1 deficiency induced brown 
adipose tissue, a specific subset of adipose tissue that promotes cardiac 
health (Laurila et al., 2016). Taken together, these data suggest that USF1 
can be an inducer of metabolic disease. Although metabolic disease and 
pigmentation are the two best described functions of USF, it has also been 
implicated as a direct regulator of retinoic acid-related orphan receptor gT 
(RORgT), a receptor that regulates the development of Th17 cells (Ratajewski 
et al., 2012).  
In chapter 3 we found that ILEI contributes to the invasive potential of 
MITF-low melanoma cells. The next question we had is whether ILEI expression 
could be altered during phenotype switching between the MITF-low invasive 
state and the MITF-high proliferative-state. We hypothesized that phenotype 
switching towards the MITF-high state would decrease ILEI expression, whereas 
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phenotype switching towards the MITF-low state would increase ILEI expression. 
Here, we demonstrate that: 1) Phenotype switching towards the proliferative 
state by MITF overexpression or vemurafenib treatment inhibits ILEI expression, 
2) Phenotype switching towards the invasive state by MITF knockdown or TGF-b 
treatment increases ILEI expression, 3) MAPK inhibition regulates ILEI 
expression at the transcriptional level, and 4) This is through the transcription 






The effect of phenotype switching on ILEI expression 
In order to test the effect of phenotype switching on ILEI expression we 
used two different models: 1) Addition of exogenous stimuli to induce a natural 
phenotype switch between the MITF-high proliferative and the MITF-low invasive 
phenotype; and, 2) Direct modulation of MITF expression to force the phenotype 
switch.  
In the first instance, we used either TGF-b, which induces the invasive 
phenotype, or the BRAF inhibitor vemurafenib, which can induce the proliferative 
phenotype in certain cell lines (Caramel et al., 2013; Pierrat et al., 2012; 
Ramsdale et al., 2015; Schlegel et al., 2015; Yang et al., 2008). When we treated 
MITF-high ILEI-low Sk-Mel-28 cells with TGF-b we observed the expected 
decrease of MITF along with an increase in ILEI expression (Fig 15A). 
Conversely, when we treated MITF-low ILEI-high WM9 cells with vemurafenib we 
observed the expected increase in MITF and DCT. The increase in DCT, which is 
a MITF target gene, suggests that the increase in MITF is functional. We also 
observed a decrease in ILEI expression (Fig 15B). In addition, we confirmed the 
vemurafenib-induced phenotype switch by observing the downregulation of the 
invasive melanoma marker ZEB1 and upregulation of the proliferative melanoma 
marker ZEB2.  
Next, we transduced MITF-high ILEI-low cells with three independent 
shRNA hairpins specific for MITF and used immunoblot analysis to observe a 
decrease in MITF and an increase in ILEI (Fig 15C). We also conducted the 
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MITF overexpression experiments in MITF-low ILEI-high cells, and used qPCR to 
observe the expected increase in MITF and DCT along with a decrease in ILEI 
(Fig 15D-E). These data not only suggest that MITF regulates ILEI during 
phenotype switching, but that ILEI might also regulate MITF. To test this 
possibility we transduced MITF-low ILEI-high cells with shRNA specific for ILEI, 
and we did not observe any change in MITF expression (Fig 15F). Based on 
these findings we conclude that modulation of MITF regulates ILEI expression, 
but ILEI does not regulate MITF.  
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Fig 15. The effect of phenotype switching on ILEI expression. A. Immunoblot 
PCR analysis of MITF and ILEI levels in ILEI-low Sk-Mel-28 cells treated with 
TGF-b (0 to 48 h, 5 ng/ml). B. Immunoblot and PCR analysis of MITF, DCT, ILEI, 
Actin, phospho-ERK T202/Y204, total ERK, and GAPDH levels in ILEI-high WM9 
cells treated with vemurafenib (BRAFi, 0 to 48 h, 1 μM). C. Immunoblot analysis 
of MITF and ILEI levels in ILEI-low 501-Mel or WM983B cells stably expressing 
scrambled shRNA or three independent shRNA hairpins specific for MITF. D. 
Immunoblot and PCR analysis of MITF, ILEI, and DCT levels in WM9 stably 
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levels in 1205Lu cells transiently expressing empty vector or MITF. N = 3, mean 
+/- SD, mRNA levels normalized to GAPDH, * indicates p < 0.05 by unpaired 
Student’s t-test. F. PCR analysis of MITF and ILEI levels in WM9 and 1205Lu 
expressing shSCR or shILEI 3.  
 
Other regulators of ILEI expression 
AKT signaling, high autophagy, and inhibition of proteasomal degradation 
have been reported to promote ILEI expression (Chaudhury et al., 2010; Hussey 
et al., 2011; Kraya et al., 2015; Sun et al., 2016). In order to know if any of these 
other factors could regulate ILEI expression in our system so we began by 
testing AKT signaling. ILEI-high cells were low for PTEN, an inhibitor of AKT 
signaling, and high for phosphorylated AKT (Fig 16A). However, when two 
independent shRNA hairpins were used to stably knockdown PTEN in PTEN-
expressing/ILEI-low cells we did not see any change in ILEI expression (Fig 16B). 
Knockdown of PTEN, an inhibitor of AKT signaling, should enhance AKT 
phosphorylation. However, AKT phosphorylation was only modestly increased, 
which suggested either that PTEN knockdown was inefficient or additional 
compensatory mechanism were making up for the PTEN knockdown. In order to 
address this concern, siRNA was used to transiently knockdown PTEN in PTEN-
expressing/ILEI-low Sk-Mel-28 cells, but there was no change in ILEI expression 
(Fig 16C). In the transient siRNA experiments phosphorylation of AKT was 
observed, suggesting the PTEN knockdown was functionally effective. An 
alternate possibility is that PTEN loss is necessary but not sufficient to induce 
ILEI expression. In this case, PTEN overexpression should inhibit ILEI 
expression. However, when PTEN was overexpressed in PTEN-null/ILEI-high 
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WM9 melanoma cells there was no change in ILEI expression (Fig 16D). Finally, 
Sk-Mel-28 melanoma cells were treated with the PI3K inhibitor LY-294002 to 
attenuate AKT phosphorylation, but again there was no change in ILEI 
expression (Fig 16E). These results suggested that AKT signaling did not 
contribute to ILEI expression in melanoma cell lines.  
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Fig 16. The contribution of PTEN to ILEI expression. A. Immunoblot analysis 
of PTEN and AKT levels in WM3912, WM983, 501-Mel, Sk-Mel-28, WM793, 
1205Lu, and WM9 cells. B. Immunoblot analysis of PTEN, AKT, and ILEI levels 
in ILEI-low WM3912 cells expressing shSCR, shPTEN 1, or shPTEN 2. C. 
Immunoblot analysis of PTEN, AKT, ILEI, and GAPDH levels in Sk-Mel-28 cells 
transiently transfected with siCTRL or siPTEN. D. Immunoblot analysis of PTEN, 
AKT, ILEI, and GAPDH levels in ILEI-high WM9 cells stably transfected with 
vector or PTEN (no tag) overexpression vector.  
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Next, we tested the contribution of autophagy to ILEI expression. We 
measured autophagic flux by using chloroquine (CQ) treatment to inhibit 
lysosomal degradation followed by immunoblot analysis for LC3B (Microtubule-
associated proteins 1A/1B light chain 3B), a known target of autophagic 
degradation. CQ-mediated inhibition of lysosomal degradation allows 
accumulation of LC3B and the relative accumulation is considered a measure of 
active autophagy or autophagic flux (Klionsky et al., 2012). We found that CQ 
treatment increased LC3B in ILEI-low cells more than ILEI-high cells, which 
suggested that ILEI-low cells had higher autophagic flux (Fig 17A). This finding is 
consistent with ILEI-low cells expressing high PTEN, which is a positive regulator 
of autophagy (Fig 16A).  
Finally, it has been shown that ILEI can be degraded by the ubiquitin 
proteasome system (Sun et al., 2016). Thus, we treated cells with MG-132 to 
inhibit proteasomal degradation. We confirmed the efficacy of the MG treatment 
by observing an increase in a high molecular weight ubiquitin smear, which 
suggested an accumulation of ubiquitinated substrates (Fig 17B). However, we 
did not see any change in ILEI, suggesting that ILEI is not degraded by the 
proteasome in melanoma cell lines. 
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Fig 17. The relationship between autophagy and the 
ubiquitin/proteasome system with ILEI expression. A. Immunoblot 
analysis of LC3B and ILEI levels in ILEI-low 501-Mel or ILEI high 1205Lu cells 
treated with chloroquine (lysosomal inhibitor, 100 μM, 1h). I and II indicate 
LC3B pre-lipidation or post-lipidation, respectively. B. Immunoblot analysis of 
ubiquitin and ILEI levels in ILEI-low WM983B or ILEI-high 1205Lu cells 
treated with MG-132 (proteasomal inhibitor, 10 μM, 0 to 2h).  
 
The effect of MAPK modulation on ILEI expression 
Because the effect of vemurafenib on ILEI expression was more robust 
than the other models of phenotype switching, I chose to use vemurafenib 
treatment to decipher the mechanism of ILEI expression in melanoma cells (Fig 
15B). WM983B melanoma cell lines were treated with vemurafenib (1 µM; 0 to 48 
h) and observed that ILEI protein expression decreased around 24 hours (Fig 
18A). Based on the time course, we hypothesized that MAPK signaling is 
involved in the transcriptional regulation of ILEI. We also conducted RT-PCR 
using primers for total ILEI mRNA, as well as primers targeting an intronic 
sequence of ILEI to amplify pre-RNA (Fig 18A). If ILEI mRNA levels are 
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should be affected by vemurafenib. However, we saw that vemurafenib treatment 
(1 µM; 0 to 48 h) decreased both ILEI total and pre-RNA, suggesting that 
vemurafenib affected ILEI transcription. In order to confirm that these findings 
were not due to off-target effects of vemurafenib we conducted a control 
experiment in which we used the BRAF WT WM3918 melanoma cells. 
Vemurafenib is specific to oncogenic BRAF, and it does not affect wild-type 
BRAF (Tsai et al., 2008). Therefore, BRAF WT WM3918 melanoma cells were 
treated with vemurafenib, which should still retain all the non-specific 
vemurafenib effects but not include any effects due to BRAF. We found that 
vemurafenib did not affect ERK phosphorylation or ILEI protein expression in 
these cell lines (Fig 18B). Next, a dose response experiment was conducted with 
501-Mel melanoma cells in which the cells were treated for 24h with 0 up to 1 µM 
of vemurafenib. ILEI inhibition could be seen starting at 0.1 µM but reached a 
clear effect at 1 µM (Fig 18C). Considering that ILEI is a secreted cytokine, the 
physiological relevance of vemurafenib-mediated inhibition of ILEI expression 
was tested by conducting immunoblot analysis of the conditioned medium. These 
results confirmed that vemurafenib decreased secreted ILEI levels (FIG 18D). 
These results were confirmed by a quantitative method using real-time qPCR 
and found that vemurafenib decreased ILEI expression in 1205Lu cells but not in 
BRAF wild-type WM3918 cells (Fig 18E). Finally, in order to further prove that 
this effect was specific for the MAPK/ERK pathway a second inhibitor of the 
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MAPK pathway (U0126, MEKi, 10 µM; 0 to 48h) was used and observed that 










Vem (µM) 0 0.01 0.1 1
PCR: Actin
PCR: ILEI total RNA
PCR: ILEI pre-RNA
c

















PCR: ILEI total RNA
PCR: ILEI pre-RNA
a WM983B


































Fig 18. The effect of vemurafenib (BRAFi) on ILEI expression. A. Immunoblot 
and RT-PCR analysis of ILEI, p-ERK, ERK, GAPDH, and Actin levels in 
WM983B melanoma cell lines treated for 0 to 48 h with vemurafenib (1 µM). 
PCR: ILEI intron indicates that PCR primers targeted the pre-RNA but not mRNA 
of the ILEI gene. B. Immunoblot analysis of ILEI, p-ERK, ERK, and Tubulin levels 
in WM3918 melanoma cell lines treated for 24h with vemurafenib (0-5 µM). C. 
RT-PCR analysis of ILEI and GAPDH levels in 501-Mel melanoma cell lines 
treated for 24h with vemurafenib at the indicated concentration. D. Immunoblot 
analysis of ILEI, p-ERK and ERK levels in WM9 melanoma cell lines treated for 0 
or 24h with vemurafenib (1 µM). IB CM indicates that serum-free medium 
condition for 24h during vemurafenib treatment was harvested and TCA 
precipitated for immunoblot analysis. E. Quantitative RT-PCR analysis of ILEI 
levels in 1205Lu or WM3918 melanoma cell lines treated for 24h with 
vemurafenib (1 µM). N=3, mean +/- SD, * indicates p<0.05 by Student’s T-test, 
transcript values are normalized to GAPDH. F. Immunoblot and RT-PCR analysis 
of ILEI, p-ERK, ERK, GAPDH, and Actin levels in WM9 melanoma cell lines 
treated for 0 to 48h with U0126 (MEKi, 10 µM).  
 
 We reasoned that MAPK signaling could be affecting FAM3C mRNA 
levels either through transcriptional or post-transcriptional mechanisms. To 
address this question we cloned two FAM3C mRNA reporter constructs, one for 
the FAM3C promoter and a second for the FAM3C 3’ UTR. We cloned the 
FAM3C promoter from 2,300 base pairs upstream of the transcription start site 
(TSS) to 80 base pairs upstream of the TSS into pBV-Luc (pBV-Luc was a gift 
from Bert Vogelstein [Addgene plasmid #16539]) (He et al., 1999), the FAM3C 
3’-UTR from the stop codon to the end of the mRNA at 1,620 base pairs was 
cloned into pmirGLO Dual Luciferase (RAB14 3’ UTR WT was a gift from Curt 
Civin [Addgene plasmid # 61489]; FIG 19A).  
501-Mel cells were transfected with either the FAM3C promoter or 3’-UTR 
luciferase reporter constructs and treated the cells with vemurafenib (24h, 0 to 1 
µM, FIG 19B). Vemurafenib decreased the FAM3C promoter activity, but not the 
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3’-UTR activity. This suggested to us that vemurafenib affected ILEI expression 
by modulating transcription. As further controls, 501-Mel cells were transfected 
with the FAM3C promoter reporter construct and found inhibition of promoter 
reporter activity by the MEK inhibitor U0126 (24h 0 to 10 µM) but not the PI3K 
inhibitor LY-294002 (24h (0 to 5 µM; FIG 19C). From these experiments I 
concluded that MAPK but not PI3K signaling could regulate ILEI mRNA at the 
transcriptional level.  
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Fig 19. The effect of vemurafenib (BRAFi) on FAM3C mRNA luciferase 
reporter activity. A. Design of FAM3C promoter and 3’ UTR luciferase reporter. 
The promoter reporter construct spans 2300 base pairs upstream of the TSS to 
80 base pairs upstream of the TSS. The 3’ UTR reporter construct spans the full 
length of the 3’ UTR. B. Luciferase assay of FAM3C promoter and 3’ UTR 
reporter constructs in 501-Mel melanoma cell lines treated for 24h with 
vemurafenib (indicated concentration). N=3, mean +/- SD, * indicates p<0.05 by 
Student’s T-test. C. Luciferase assay of ILEI promoter construct in 501-Mel 
melanoma cell lines treated for 24h with U0126 (MEKi) or LY-294002 (PI3Ki). 
Relative luciferase activities were calculated to constitutively active CMV-Renilla 
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Since inhibition of MAPK/ERK decreases ILEI expression, I next wanted to 
know the converse: whether activation of MAPK/ERK could increase ILEI 
expression. EGF treatment was used as a model for MAPK/ERK activation. 
Luciferase assays were conducted using 501-Mel melanoma cells serum starved 
overnight and treated with EGF (50 ng/ml, 0 up to 24h; Fig 20A. To our surprise, 
there was no effect of EGF treatment on FAM3C promoter activity. The EGF-
mediated induction of phospho-ERK was confirmed by immunoblot (Fig 20B). 
However, TGF-β treatment (5 ng/ml, 24h) increased FAM3C promoter activity. 
From these experiments I concluded that a pathway activated by TGF-β and 
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Fig 20. The effect of EGF or TGF-β on FAM3C promoter reporter activity. A. 
Luciferase assay of FAM3C promoter reporter construct in 501-Mel cells serum 
starved overnight, and treated with EGF (50 ng/ml) or TGF-β (5 ng/ml) for 0 up to 
24h. N=3, mean +/- SD, n.s. indicates p>0.05 and * indicates p<0.05 by 
Student’s t-test as compared to 0h treatment. B. Immunoblot analysis of ERK 
levels in 501-Mel cells serum starved overnight, and treated with EGF (50 ng/ml) 
for 0 up to 24h.  
 
The contribution of cis elements to the activity of FAM3C transcriptional 
reporters 
 Because we observed that MAPK regulates ILEI at the transcriptional level, 
we hypothesized that this might be due to a cis-element in the FAM3C promoter 
region. We took the FAM3C promoter 2,300 base pairs from the TSS and 
searched it for various transcription factor motifs using the JASPAR database 
(Mathelier et al., 2016). We focused our transcription factor search by identifying 
three key motifs that may be involved in ILEI expression. Given our data that ILEI 
contributes to the biology of MITF-low ILEI-high cells, we focused our 
transcription factor search on motifs (E-box [ZEB1], JUN, and TEAD4) known to 
contribute to the MITF-low ILEI-high invasive phenotype (Caramel et al., 2013; 
Denecker et al., 2014; Ramsdale et al., 2015; Richard et al., 2016; Riesenberg et 
al., 2015; Verfaillie et al., 2015). We found 11 putative E-box, 5 JUN, and 3 
TEAD4 sites in the FAM3C promoter (FIG 21A).  
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Fig 21. FAM3C promoter transcription factor motifs. A. Putative E-box, JUN, 
and TEAD4 binding motifs in the first 2,300 base pairs of the human FAM3C 
promoter. Motifs were predicted using JASPAR (Mathelier et al., 2016).  
 
 Several FAM3C reporter constructs were generated, starting from 2,300 
base pairs upstream of the transcriptional start site with successive 5’-deletions 
starting with the full-length -2,300/-80 construct, then a 2,000 bp truncation to the 
-300/-80 construct, at which point we designed strategic truncation to eliminate 
each of the remaining transcription factor binding sites. These construct were 
transfected into 501-Mel cells and found that elimination of a region from 204 to 
FAM3C promoter from 2300 base pairs upstream of the transcription start site:
TCTCCAAATACTCCATCAGTGTATCCTCTCCCCAGGTGATGCCTTTGTTCTTAATGGCATCTGTGTAAAATAATCCAACGGCTTGACCTGTCTTCCATCC  < -2200
E-box           E-box
GAAGAGACCATGGAGATTAGGCCCAGTCCTGTGCTTGCCTGCCTTTTCCACAGTGTGGCACTGGGCACACTTCTGAATACAAATCTTCTTGCCTTTCTCA  < -2100
ACATCATCCATATTTAATCCTCTCTTTTGTTGCTTGTGCTATGAAGGATGACACTCAGAAGCTGGATGTCACACTCTCTGTATATTCTTTTCGAGTCAAC  < -2000
AAAAAAGTTGGGCTTTGAAGTTGAGCACGTGAGTTTGAATCTTAGCTCTGTCTGGTCATAGCAGAAGGACCTTGAGCAAGTTTCACTTTTCTCCGCTGTA  < -1900
E-box
TTTATAGGATTATTGTGAGAATTAAATAAGTCTATATATATAAAGTGCTTAGAAAAGTGCCTGGTGCACAATAAGCACACAATAAATATCAGCTTTAGAA  < -1800
ATATACATTATCAGTAGCTATTATTATATAATATAAATTATCGGTAGTTATTGTAATAGCCAACACCTTTGGCTTATACCTCCTGGAGCTGTAAAGCTCT  < -1700
GTGGTTTTATTAAGCTTAATCATTAATCCTGAATACTTCTCCTGGCTCCCCTACCTCCTGCCAAGTAAAAGTAGGAAGTTATCCTTACTCGTTTATAGGT  < -1600
GTAAGAACTGGCTGATTAACAGGAGTCCTAAAGAAGTGATTTACCAATGTTAAAAAAATTGAAACCCATATTAAGAAATATAATTTCTACTGTATCCAGG  < -1500
ACATAGACACACAGACACTCACCCACACATGATGCTGTACAAATGTTTCATGAAGAATACTTATCCTGAATTTATGCTTTGAACTGTTTTTTTTTTCTAT  < -1400
E-box              E-box
TTTTCAGTGAATCAACAGCAACAAAATGTTGGTTGTGACCCATTGTTATTAATTTCATTACCTACCAAAGGGTTCTAAGCTATATCTTATGGTCAGTGGA  < -1300
JUN JUN




GTACAGTAAGTGTTATGATTTTTTGGTACTATAATAAGCAAAGTGCCTTTTTGTTTATTTGGAGCTACATGAAGCTAGGCCGGAATTCCAGCTTCATAAC  < -1000
TEAD4
TTACTATCTTGTATTTTTGAGCAAGATATTTAAACTCAGTTTTGGAGTCTTAGTTTTTTGATTTAAGTAATACACAAATAGCATAATATTGGCACATGGA  < -900
E-box
AGACAATGAGAATTCATTTCATGCTTTCTCCCCTGATCACGGATCACAAACTCCAGAATTCATAGTTACTATTAGTTTGTGTGTTTTATATTTTTGGAGG  < -800
AAAGCTAAAATTTGGTAGATTATTAATTCTATATTAACACACTATAGTCAAACCCTATTTTTAAATGCAATTTAATTTCTGCAACCACTGATGATCCCAA  < -700
TATTCTGTCAAATACTAGGTAACAGTTATTCATTATTTTAGAATATGGATCTGAATTATGAAATAATTTTGCATTCTAAGGTCTTATGTAGTAAGATTTG  < -600
GATTAACTTCCCAATTATCAACACAATTGTAGGAAATCTCCTGAGAAAAAATATTTCTAACGATTGTGTATCTTATAATTTAAAAAATAAACGTGACTTG  < -500
E-box
GAAAATGCAAGGACTACTGTTCTTCTTGGGTGGTGCATTAAAGGTGATCAGAATTCTAATGACGCTGGACAGTAGGATTTTCAGAATCAGTTTCCTAGGG  < -400
TEAD4
TTCAAGAAGTCAAACGGCAAATAACCCAAGGTCCTTGGTTGATCTGACCATCTCAGCTATCTCAAGATATATAAGATGACCTAACTGGCGCATCTCTAGG  < -300
JUN
ATGGGTGGGTCATTTAAAATGTTCTGCCCTTGAGGCTGGGATTTTGTGCGTGTAAACGGTGGGGAGACGGCGGTGACACATTTTTCTCCCTCCCGTAGTG  < -200
JUN JUN
CCACCCGGCGCAGGGCCGCTGCGGCGGCGGCAGCTCCCACGTGGCAAGTTCAGATTGTGCAGCGCCTGGCCGGGGGCGGTGGGCGGGACCGCAGACCCCT  < -100
E-box          TEAD4
CCCTCCGCTCTCCGGCCCTTCCCTCTGGCCGGCCCGGGCGCCCGCTTGGTCCTCCACCGCCAGGGGGCGGGCGCGGCTTCCCGGCGGCGGGGGCCCATTG  < TSS
a
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150 base pairs upstream of the TSS was critical for basal FAM3C promoter 
activity (Fig 22A). This region contained an E-box, so site-directed mutagenesis 
was conducted on the E-box in the -300/-80 construct (all primers listed in Table 
1). The construct was sequenced and inputted into the sequence in the JASPAR 
database to find that the mutation abolished all predicted binding to this region 
(data not shown). Mutation of the E-box in the -300/-80 construct inhibited 
luciferase activity in several melanoma cell lines (Fig 22B). Additionally the site-
directed mutagenesis was repeated in the -2300/-80 construct to see if this 
specific E-box was important for the regulation, or if E-box motifs at other 
locations could substitute for this most proximal E-box. Mutation of just the 
proximal E-box inhibited the luciferase activity in the 501-Mel melanoma cells 
(Fig 22C). Finally, a promoter alignment comparing the first 300 base pairs of 
FAM3C in human and mouse revealed conservation of the E-box sequence, as 
well as the 9+ nucleotides flanking the site (Fig 22D).  
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Fig 22. The contribution of cis elements to FAM3C promoter reporter basal 
activity. A. Luciferase assay of various length FAM3C promoter reporter 
constructs in 501-Mel melanoma cell lines. N=3, mean +/- SD, * indicates p<0.05 
by Student’s T-test as compared to the promoterless construct. B. Luciferase 
assay of FAM3C promoter reporter constructs in 501-Mel melanoma cell lines. 
Black bars indicate wild-type promoter (-300/-80) and white bars indicate E-box 
mutant (-300/-80). N=3, mean +/- SD, * indicates p<0.05 by Student’s T-test. C. 
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-2300/-80 mut E-box 
* 
b c 
Hsa -300 TGGGTGGGTCATTTAAAATGT-TCTGCCCTTGAGGCTGGGATTTTGTGCGTGTAAACGGTGGGGAGACGGCGGTGACACATTTTTCTCCCTCCCGTAGTGCCACCCGGCGCAGGGCC--GCTGCGG -177
         ||.|||.||        .||| |.||    ||.|..||.|..|.||||.|||| .||.|..|||.|..||||.|||||||||||.||.||||||...|||||     .|.||||.||  |||||||
Mus -300 TGTGTGTGT--------GTGTGTGTG----TGTGTGTGTGTGTGTGTGTGTGT-GACTGAAGGGCGGAGGCGCTGACACATTTTCCTTCCTCCCCGGGTGCC-----TCTCAGGTCCTGGCTGCGG -192
     E-box 
Hsa -176 CGGCGGCAGCTCCCACGTGGCAAGTTCAGATTG---TGCA---GCGCCTGGCCGGGGGCGGTGGGCGGGACCGCAGACCCCTCCCTCCGCTCTCCGGCCCTTCCCTCTGGCCGGCCCGGGCGCCCG -56
         ..||||||||||||||||||||||||||.||||   .|||   |||.|   |||||..|  |.|||||                       ||..||.||||||..|.||  |.||...|||.|.|
Mus -191 ACGCGGCAGCTCCCACGTGGCAAGTTCACATTGAGTCGCAGACGCGAC---CCGGGATC--TTGGCGG-----------------------CTGTGGTCCTTCCTCCAGG—GACCTCAGCGTCGGG -93
Hsa  -55 CTTGGTCCTCCACCGCCAGGGGGCGGGCGCGGCTTCCCGGCGGCGGGGGCCCATTGGT---------------------------------------- 0
         ||.||||||||||||||||||||||.||||||||.|.|||..| .|| ||.||||||. 



















cell lines. Black bars indicate wild-type promoter (-2300/-80) and white bars 
indicate E-box mutant (-2300/-80). N=3, mean +/- SD, * indicates p<0.05 by 
Student’s T-test. D. Sequence homology of the first 300 base pairs of the FAM3C 
promoter in human and mouse. Blue box indicates a conserved E-box.  
 
The FAM3C reporter truncation constructs described in Fig 20 were used 
in luciferase assays using 501-Mel melanoma cells treated with DMSO control or 
vemurafenib (24 h, 1 µM). Similar to the basal activity, truncation of the E-box 
inhibited the vemurafenib responsiveness (Fig 23A). LY-294002 (PI3Ki, 5 µM) 
was used as a negative control and LY treatment did not affect FAM3C promoter 
activity. Again, the FAM3C promoter reporter wild-type and mutant E-box were 
used in luciferase assays using 501-Mel melanoma cells treated with DMSO 
control or vemurafenib (24 h, 1 µM). The FAM3C mutant E-box promoter reporter 
activity still showed vemurafenib responsiveness, but this responsiveness was 
attenuated in comparison to the wild-type E-box. This attenuation was seen in 
both the -300/-80 construct as well as the -2300/-80 construct (Fig 23B).  
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Fig 23. The contribution of cis elements to FAM3C promoter reporter 
vemurafenib responsiveness. A. Luciferase assay of various length FAM3C 
promoter reporter constructs in 501-Mel melanoma cell lines. Black bars indicate 
control DMSO treatment and white bars indicate 24h treatment with 
vemurafenib(1 µM). N=3, mean +/- SD, * indicates p<0.05 by Student’s T-test as 
compared to promoterless construt. B. Luciferase assay of wild-type and E-box 
mutatnt FAM3C promoter reporter constructs in 501-Mel melanoma cell lines. 
Black bars indicate control DMSO treatment and white bars indicate 24h 
treatment with vemurafenib(1 µM). N=3, mean +/- SD, * indicates p<0.05 by 
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The effect of USF-1 on ILEI expression 
 Given the importance of the E-box motif to both ILEI basal transcription as 
well as vemurafenib responsiveness, we wanted to know what regulated ILEI 
transcription through this E-box. To this end, different transcription factors that 
are known to bind E-box motifs to regulate transcription were overexpressed, and 
USF-1 was found to increase FAM3C promoter reporter activity but not c-MYC, 
N-MYC, L-MYC, TFEB, TFE3, MITF, CREB3L2, ID2 (Fig 24A). Next, USF-1 was 
overexpressed to test its ability to rescue vemurafenib-mediated inhibition of 
FAM3C promoter reporter activity. Vemurafenib responsiveness was present in 
the vector-transfected cells, but not in the USF-1 transfected cells (Fig 24B). 
Interestingly, vemurafenib treatment enhanced USF-1-mediated transcriptional 
activation. This is likely because vemurafenib treatment is known to increase 
signaling through p38 MAPK signaling, and p38 MAPK is a known activator of 
USF-1 (Galibert et al., 2001; Ramsdale et al., 2015). Finally, to test if USF-1 was 
relevant to the regulation of endogenous ILEI, USF-1 was overexpressed and 
found to increase basal ILEI expression and also attenuate vemurafenib-
mediated ILEI inhibition (FIG 24C). These results suggested that USF-1 was 
important for both basal activity as well as vemurafenib responsiveness.  
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Fig 24. The effect of E-box binding transcription factors on FAM3C 
promoter reporter basal activity and vemurafenib responsiveness. A. 
Luciferase assay of FAM3C promoter reporter construct (-300/-80) in 501-Mel 
melanoma cell lines. 0, 0.05, 0.1, or 0.2 µg of experimental vector and a 
corresponding 0.2, 0.15, 0.1, or 0 µg of empty vector was transfected for 24h. 
White bars indicate 0, light grey bars indicate 0.05, dark grey bars indicate 0.1, 
and back bars indicate 0.2 µg of experimental vector. Luminescence is 
normalized to vector control for each transcription factor. N=3, mean +/- SD, * 
indicates p<0.05 by Student’s T-test as compared to vector transfection. B. 
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Luciferase assay of wild-type and E-box mutant FAM3C promoter reporter 
construct (-300/-80) in 501-Mel melanoma cell lines treated for 24h with 
vemurafenib (1 µM). Black bars indicate DMSO treatment and white bars indicate 
vemurafenib (1 µM). Luminescence is normalized to DMSO treatment. N=3, 
mean +/- SD, * indicates p<0.05 by Student’s T-test as compared to DMSO 
treatment. C. Immunoblot analysis of ILEI, V5, phospho-ERK, total ERK, and 
tubulin in 501-Mel melanoma cells transfected with either vector or USF-1 and 
treated with vemurafenib (24h).  
 
Next, to confirm that ILEI was a direct target of USF-1 chromatin 
immunoprecipitation were conducted on endogenous USF-1 from 501-Mel cells. 
The FAM3C promoter sequence from 204 to 80 base pairs upstream of the TSS 
was detected in the USF-1 immunoprecipitate (Fig 25A). In addition, the 
pigmentation gene TYR (tyrosinase) promoter was detected in the USF-1 
immunopreciptate while HMOX1 (heme oxygenase 1 or HO1) promoter was not 
detected. TYR was shown to be a USF-1 target gene in melanoma cell lines, 
whereas HMOX1 was shown to be a USF-1 target gene in epithelial cell lines 
(Corre et al., 2004; Galibert et al., 2001; Hock et al., 2004). Additionally biotin 
pulldown experiments were conducted with biotin-tagged FAM3C promoter 
constructs from 200 to 110 base pairs upstream of the TSS. The wild-type 
construct, but not a mutant E-box construct was able to pulldown USF-1 (FIG 
25B). From these experiments we conclude that the FAM3C promoter is a direct 
target of USF-1 and that this interaction is dependent on the E-box.  
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Fig 25. The ILEI promoter is a direct target of USF-1. A. ChIP analysis of 501-
Mel melanoma cell lines immunoprecipitated with USF-1 antibody. PCR was 
conducted for various promoter sequences as indicated. B. Biotin pulldown 
analysis of 501-Mel melanoma cell lines using FAM3C promoter oligo either wild-
type or mutant for the E-box. SCR indicates a random 60 nucleotide oligo 
coupled to biotin used as a negative control.  
 
 Finally, considering that USF-1 is a transcriptional regulator of ILEI, 
immunoblot were conducted to test the levels of endogenous USF1 in the 501-
Mel ILEI-low and WM9 ILEI-high melanoma cell lines. ILEI-high WM9 cells had 
higher expression of USF-1 compared to ILEI-low 501-Mel cells (Fig 26A). 














Fig 26. USF-1 expression in ILEI-low and ILEI-high melanoma cells. A. 
Immunoblot analysis of ILEI, USF-1, and GAPDH in ILEI-low 501-Mel or ILEI-




More and more literature is accumulating to suggest that ILEI is an 
important contributor to EMT and cancer progression in several different cancer 
types, neurodegenerative disease, bone development, and metabolic diseases 
(Bendre et al., 2016; Chen et al., 2017; Csiszar et al., 2014; Gao et al., 2014; 
Hasegawa et al., 2014; Lahsnig et al., 2009; Liu et al., 2016; Maatta et al., 2016; 
Song et al., 2014; Waerner et al., 2006; Zhu et al., 2015). However, there is little 
known about transcriptional regulation about ILEI. To date there are three known 
regulators of ILEI: the first is translational regulation of ILEI by TGF-
b/AKT2/hnRNP-E1, the second is degradation of ILEI by the 
ubiquitin/proteasome system, and the third is an autophagy-mediated increase in 
ILEI protein expression (Chaudhury et al., 2010; Kraya et al., 2015; Sun et al., 
2016). Based on the data presented herein, we believe that neither of these three 
mechanisms are responsible for regulation of ILEI in the melanoma cell line 
model (Fig 15).  
First, translational regulation of ILEI by TGF-b/AKT2/hnRNP-E1 was 
originally described in a breast cancer model and we did not observe any 
evidence of AKT-mediated regulation of ILEI expression (Fig 16). Second, 
degradation of ILEI by the ubiquitin/proteasome system was originally described 
in a prostate cancer model and we did not observe any effect of MG-132-
mediated proteasome inhibition on ILEI expression in the melanoma cell line 
model (Fig 17). In addition, it is possible that the original paper describing 
proteasome-mediated ILEI degradation identified a non-specific ILEI band as the 
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ILEI band (Sun et al., 2016). In one co-immunoprecipitation experiment the 
authors label a band running above the IgG light chain as the ILEI band. 
Typically the light chain runs at 25 kDa, and we find that intracellular ILEI runs 
around 23 kDa (Fig 3). It is possible that prostate cancer cells process ILEI 
differently and that ILEI runs at a different molecular weight in these cell lines. 
However, to clarify whether the authors are identifying the correct ILEI band, it is 
of the utmost importance to conduct control experiments to ensure the specificity 
of the ILEI antibody. Finally, in regards to the autophagy-mediated increase in 
ILEI expression, this was described in a melanoma cell line model identical to the 
one in this study (Kraya et al., 2015). They show that highly autophagic 
melanoma cells have high ILEI secretion, and they further use an exogenous 
Beclin peptide as well as siRNA against ATG7 to modulate autophagy and ILEI 
secretion. The initial finding in this paper comes from a comparison between low-
autophagy WM793 cells with its highly autophagic metastatic derivative (1205Lu), 
which shows that the highly autophagic 1205Lu cells have higher ILEI expression 
than WM793 cells. However, in regards to the finding that 1205Lu cells have 
higher autophagic activity than WM793 cells, we respectfully question the validity 
of the experiments used to measure autophagic activity. First, the authors 
conduct electron microscopy to measure the number of vacuoles as a measure 
of autophagy. However, whether the vacuoles are true double-layered 
autophagic vacuoles is difficult to discern at this resolution. Second, the authors 
conduct immunofluorescent microscopy to measure a tandem RFP-GFP-tagged 
LC3. The basis of this assay is that GFP is more acid sensitive than RFP, so the 
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RFP-GFP construct will appear yellow in autophagosomses, but appear red 
when the acidic conditions of the lysosome inactivate the GFP. Accordingly, the 
authors show an increase of red dots in the 1205Lu cells. However, there is no 
confirmation of the absolute expression levels of the mCherry-eGFP-LC3 
construct in both cell lines. In my experience the transfection efficiency of the 
1205Lu cells is higher than WM793 (data not shown), and the mCherry-eGFP-
LC3 construct expression levels serve as an important variable in this experiment. 
Finally, the authors conduct LC3 immunoblot analysis to compare LC3-I and 
LC3-II levels. However, autophagic activity is not indicated by the absolute 
expression levels of LC3, but rather the change in LC3 upon treatment with 
lysosomal inhibitors such as chloroquine (Mizushima and Yoshimori, 2007). 
Based on these experimental caveats, we believe that the autophagic activity of 
1205Lu compared to WM793 cells cannot be concluded from these studies. In 
addition, we have conducted one experiment of our own concerning the 
correlation between ILEI and autophagic activity. This experiment was based on 
our finding that ILEI expression is high in PTEN null cells (Fig 16). Considering 
that PTEN is a negative regulator of AKT/mTOR signaling, and mTOR is a 
negative regulator of autophagy, we hypothesized that PTEN null cells would 
have low autophagic activity, and thus low autophagic activity would correlate 
with high ILEI expression. We tested this by treating PTEN wild-type ILEI-low 
501-Mel cells or PTEN null ILEI-high 1205Lu cells with chloroquine to inhibit 
lysosomal breakdown of autophagic vacuoles and thus measure autophagic flux. 
We observed that there was more accumulation of LC3-II in PTEN wild-type ILEI-
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low 501-Mel cells than PTEN null ILEI-high 1205Lu cells. While we recognize 
that this experiment just uses one cell line each of ILEI-low and ILEI-high, we still 
conclude, with caution, that autophagic flux is higher in ILEI-low cells. 
A major goal of this dissertation was to characterize the first transcriptional 
regulator of ILEI. We started with the finding that phenotype switching mediated 
by multiple mechanisms regulates ILEI expression, and we selected the most 
robust regulator of ILEI, vemurafenib, with which to conduct mechanistic studies 
(Fig 15, 18). Vemurafenib and other inhibitors of the MAPK/ERK pathway are 
known to regulate phenotype switching towards the MITF-high proliferative state 
in certain melanoma cell lines (Caramel et al., 2013; Denecker et al., 2014). We 
used luciferase assays and promoter analysis to find that the vemurafenib-
mediated regulation of ILEI occurred at the transcriptional level, and this was 
partially through an E-box located 160 base pairs upstream of the transcription 
start site (Fig 19, 23). We also found that basal ILEI transcription depended on 
this proximal E-box (Fig 22). By screening E-box binding transcription factors we 
determined that USF1 regulates both basal and vemurafenib regulation of ILEI 
transcription (Fig 24). Additionally, we showed that USF1 directly interacts with 
the FAM3C promoter sequence (Fig 25). Finally, we found that MITF-low ILEI-
high cells express high levels of USF1, and MITF-high ILEI-low cells express low 
levels of USF1 (Fig 26).  
USF-1 is a stress responsive transcription factor involved in melanocyte 
pigmentation. USF-1 is involved in UV-induced, but not MITF-mediated 
constitutive pigmentation (Corre and Galibert, 2005). The non-overlapping 
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function of USF-1 with MITF in pigmentation suggests that USF-1 could play 
other roles in melanoma biology when MITF is poorly expressed, as in invasive 
melanoma cells. In addition to regulation of pigmentation, USF-1 also activates 
anti-proliferative machinery that has been shown to inhibit MYC-driven 
proliferation (Luo and Sawadogo, 1996). USF-1 is regulated by stress-mediated 
p38 MAPK, and p38 signaling is a known regulator of the invasive phenotype 
(Galibert et al., 2001; Ramsdale et al., 2015; Riesenberg et al., 2015; Verfaillie et 
al., 2015). Mechanistically, p38 phosphorylates USF1 on threonine 153, which 
activates its transcriptional activity (Galibert et al., 2001). However, p38-mediated 
phosphorylation also primes USF-1 for acetylation at lysine 199 which inhibits its 
transcriptional activity (Corre et al., 2009). Various factors regulate p38 signaling 
including TGF-b, and we have shown here that TGF-b activates ILEI expression 
at the transcriptional level (Fig 15, 20). Future work will focus on the connection 
between USF-1 and other regulators of phenotype switching such as TGF-b.  
To conclude, we found that 1) Phenotype switching towards the 
proliferative state by MITF overexpression or vemurafenib treatment inhibits ILEI 
expression, 2) Phenotype switching towards the invasive state by MITF 
knockdown or TGF-b treatment increases ILEI expression, 3) MAPK inhibition 
regulates ILEI expression at the transcriptional level, and 4) this is through the 
transcription factor USF-1.  
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Chapter 5  
Conclusions 
 
The focus of this study is ILEI (Interleukin-like EMT Inducer, FAM3C), a 
cytokine-like molecule that contributes to diverse processes including cancer 
progression, bone development, neurodegenerative disease, and diabetes 
(Bendre et al., 2016; Chen et al., 2017; Csiszar et al., 2014; Hasegawa et al., 
2014; Lahsnig et al., 2009; Liu et al., 2016; Maatta et al., 2016; Waerner et al., 
2006). ILEI contributes to cancer progression by inducing an epithelial-to-
mesenchymal transition (EMT), a normal cellular process that occurs during 
embryonic development that can be used by epithelial cells to acquire motility, 
chemoresistance, and cancer stemness (Nieto et al., 2016). In particular, I have 
focused on ILEI in melanoma because ILEI expression is elevated during 
melanoma progression (Fig 1) and also because melanoma is a neural crest 
derived tumor and there is a growing body of research focused on the ability of 
neural crest-derived cells to reactivate the EMT machinery it uses during 
development as a tumorigenesis mechanism. 
The results of this study suggest that ILEI is important to the invasive 
phenotype in a subpopulation of melanoma cells characterized by low levels of 
the master melanocyte differentiation transcription factor MITF (micropthalmia-
associated transcription factor) (Hoek, 2011). This subpopulation is known to be 
chemoresistant and invasive, similar to the mesenchymal population in an 
epithelial-to-mesenchymal transition (Carreira et al., 2006; Muller et al., 2014). 
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MITF-low cells express high levels of ILEI, and this finding is consistent wtih 
melanoma patient samples that show an inverse correlation between MITF and 
ILEI (Fig 1, 3). Because the MITF-low cells are known to be invasive, ILEI was 
knocked down in these cells and invasion was attenuated in vitro and in vivo (Fig 
4, 5). Interestingly, ILEI knockdown did not affect other aspects of phenotype 
switching including chemoresistance, proliferation, and MITF expression (Fig 4, 7, 
8, 10). Finally, gene expression analysis was conducted to find that ILEI 
regulates the expression of genes related to hypoxia, the unfolded protein 
response (UPR), and JUN signaling, all of which have been linked to the MITF-
low invasive melanoma phenotype (Falletta et al., 2017; O'Connell et al., 2013; 
Ramsdale et al., 2015; Riesenberg et al., 2015; Widmer et al., 2013). Based on 
these studies I concluded that ILEI contributes to partial phenotype switching by 
modulating invasion in MITF-low melanoma cell lines. There is a recent paper on 
phenotype switching that described inhibition of MITF by the stress-regulated 
transcription factor ATF4, but interestingly they found that ATF4 did not affect 
invasive potential (Falletta et al., 2017). Given the abundance of papers 
describing the partial or hybrid EMT phenotype it is likely that other phenotype 
switching factors will contribute to a partial phenotype switch (Grande et al., 
2015; Grosse-Wilde et al., 2015; Jolly et al., 2016; Schliekelman et al., 2015). 
This idea has potential therapeutic relevance as one could imagine a scenario in 
which therapeutic inhibition of ILEI could inhibit metastatic potential whilst not 
affecting proliferative rate, whereas a broad inhibitor of the invasive phenotype 
would both inhibit metastatic potential and increase proliferative rate.  
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A second finding from this dissertation is that ILEI is regulated by 
phenotype switching between the proliferative and invasive state, and that 
mechanistically this is regulated at the transcriptional level by upstream 
stimulatory factor 1 (USF-1; Fig 14, 22). USF-1 is an E-box binding transcription 
factor that has an important function in the melanocyte lineage as an activator of 
UV-mediated pigmentation gene transcription (Galibert et al., 2001). Considering 
that regulators of the MITF-low invasive phenotype are just starting to be 
described in the past couple years, future work should delineate the contribution 
of USF1 to phenotype switching, and how USF-1 connects to other phenotype 
switching regulators such as TGF-b (Ramsdale et al., 2015; Riesenberg et al., 
2015; Verfaillie et al., 2015).  
Combining the findings from the ILEI-mediated biology with the USF-1-
mediated ILEI regulation, we are starting to get a picture of ILEI’s physiological 
function. I speculate three possibilities, 1) ILEI functions as a stress response 
gene, 2) ILEI regulates metabolism along with other FAM3 family members, and 
3) ILEI contributes to the immunosuppressive effects of melanoma.  
The findings from the microarray gene expression analysis suggest that 
some of the major pathways activated by ILEI include hypoxia, interferon 
response, and the unfolded protein response (Fig 10). All three of these 
represent a stress response, whether to low oxygen, viral infection, or ER 
malfunction. In addition, USF is a known stress response transcription factor, 
which is upregulated by stressors such as UV light. Considering the magnitude of 
the ILEI knockdown effect between the in vitro migration/invasion and the in vivo 
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lung colonization assay it is possible that ILEI contributes to lung colonization by 
a migration/invasion-independent mechanism (Fig 4 and 5).  
A second emerging role for ILEI is metabolic regulation. Both the ILEI 
downstream pathways as well as ILEI upstream regulators can be connected to 
metabolic regulation. For instance, two hits from the ILEI regulated gene set 
enrichment analysis were AKT/mTOR and SREBP signaling. SREBP is a 
transcription factor that regulates lipid biosynthesis genes, and this is positively 
regulated by AKT/mTOR signaling (Porstmann et al., 2008). USF1 is well 
established as a regulator of metabolism, and it has been shown that USF1 
deficiency can be protective against metabolic diseases including obesity (Laurila 
et al., 2016).   
Interestingly, other cytokines of the FAM3 family including FAM3A and 
PANDER (Pancreatic-derived factor, FAM3B) contribute to metabolic regulation. 
In vivo it was shown that transgenic PANDER overexpression in mice induces 
diabetes-like symptoms including hyperglycemia and elevated insulin (Robert-
Cooperman et al., 2014). On a mechanistic level PANDER binds to the cell 
surface of hepatocytes and attenuates insulin-mediated signaling (Yang et al., 
2009). The PANDER promoter has been shown to be glucose responsive 
through an E-box binding protein, the carbohydrate-responsive element-binding 
protein (ChREBP) (Ratliff et al., 2015). Similar studies on FAM3A revealed that 
its expression was inhibited in diabetic mice and FAM3A overexpression partially 
reversed the diabetic phenotype (Wang et al., 2014). ILEI seems to behave 
similarly to FAM3A, as ILEI expression was inhibited in diabetic mice and ILEI 
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overexpression partially reversed the diabetic phenotype (Chen et al., 2017). 
One possibility is that PANDER (FAM3B) is on one side of the scale acting as an 
insulin inhibitor to increase blood glucose, whereas FAM3A and ILEI (FAM3C) 
are on the opposite side of the scale acting as an insulin-like hormone to 
decrease blood glucose. One notable difference between PANDER and FAM3A 
and ILEI (FAM3C) is that PANDER is preferentially expressed in the pancreas, 
whereas FAM3A and ILEI (FAM3C) are expressed ubiquitously. FAM3D has 
been shown to act as a neutrophil chemoattractant by signaling through its 
receptors Formyl peptide receptor 1 and 2 (FPR1, FPR2) (Peng et al., 2016). 
Formyl peptide receptors are chemotactic receptors in the G-protein coupled 
receptor family, and these receptors are primary expressed by neutrophils (Le et 
al., 2002).  
Finally, a third possible role for ILEI in melanoma is as an immune 
suppressive molecule. Inhibition of MAPK signaling by small molecules such as 
vemurafenib inhibit ILEI expression, and other groups have shown that 
vemurafenib alleviates immune suppression to promote immune-mediated tumor 
killing (Steinberg et al., 2014). Considering that vemurafenib decreases ILEI 
expression and immune suppression, one possibility is that ILEI promotes 
melanoma immune evasion by downregulating TGFBR3, which stimulates the 
tumor-targeting immune system (Fig 10, 12). Mechanistically, it has been shown 
that TGFBR3 inhibits expression of IDO, a known inhibitor of T-cell function 
(Hanks et al., 2013).  
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In conclusion, we have found that ILEI is highly expressed in MITF-low 
invasive melanoma cell lines, that ILEI regulates the invasive phenotype of these 
cells, and that ILEI is regulated during vemurafenib-mediated phenotype 
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